CA2190374A1 - Optical method and apparatus for the diagnosis of cervical precancers using raman and fluorescence spectroscopies - Google Patents
Optical method and apparatus for the diagnosis of cervical precancers using raman and fluorescence spectroscopiesInfo
- Publication number
- CA2190374A1 CA2190374A1 CA002190374A CA2190374A CA2190374A1 CA 2190374 A1 CA2190374 A1 CA 2190374A1 CA 002190374 A CA002190374 A CA 002190374A CA 2190374 A CA2190374 A CA 2190374A CA 2190374 A1 CA2190374 A1 CA 2190374A1
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- fluorescence
- calculating
- normal
- abnormality
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract 31
- 238000001069 Raman spectroscopy Methods 0.000 title claims abstract 5
- 230000003287 optical effect Effects 0.000 title claims 3
- 238000003745 diagnosis Methods 0.000 title claims 2
- 238000001506 fluorescence spectroscopy Methods 0.000 title abstract 3
- 230000005856 abnormality Effects 0.000 claims abstract 34
- 208000032124 Squamous Intraepithelial Lesions Diseases 0.000 claims abstract 16
- 238000005259 measurement Methods 0.000 claims abstract 16
- 238000002189 fluorescence spectrum Methods 0.000 claims abstract 9
- 230000005284 excitation Effects 0.000 claims abstract 7
- 238000000338 in vitro Methods 0.000 claims abstract 2
- 238000001727 in vivo Methods 0.000 claims abstract 2
- 238000001228 spectrum Methods 0.000 claims 45
- 239000000523 sample Substances 0.000 claims 31
- 230000005670 electromagnetic radiation Effects 0.000 claims 30
- 230000002159 abnormal effect Effects 0.000 claims 20
- 238000009826 distribution Methods 0.000 claims 19
- 238000005286 illumination Methods 0.000 claims 16
- 238000001237 Raman spectrum Methods 0.000 claims 14
- 238000004458 analytical method Methods 0.000 claims 14
- 238000007781 pre-processing Methods 0.000 claims 10
- 230000001131 transforming effect Effects 0.000 claims 7
- 239000011159 matrix material Substances 0.000 claims 6
- 206010058314 Dysplasia Diseases 0.000 claims 3
- 230000000875 corresponding effect Effects 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 238000011068 loading method Methods 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 238000000513 principal component analysis Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000001360 synchronised effect Effects 0.000 claims 1
- 238000012762 unpaired Student’s t-test Methods 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 2
- 230000035945 sensitivity Effects 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010054949 Metaplasia Diseases 0.000 abstract 1
- 238000001574 biopsy Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000015689 metaplastic ossification Effects 0.000 abstract 1
- 238000002095 near-infrared Raman spectroscopy Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/43—Detecting, measuring or recording for evaluating the reproductive systems
- A61B5/4306—Detecting, measuring or recording for evaluating the reproductive systems for evaluating the female reproductive systems, e.g. gynaecological evaluations
- A61B5/4318—Evaluation of the lower reproductive system
- A61B5/4331—Evaluation of the lower reproductive system of the cervix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
- A61B5/0086—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters using infrared radiation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
- G01N2021/653—Coherent methods [CARS]
- G01N2021/656—Raman microprobe
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Abstract
A method and apparatus for detecting tissue abnormality, particularly precancerous cervical tissue, through fluorescence or Raman spectroscopy, or a combination of fluorescence and Raman spectroscopy. In vivo fluorescence measurements were followed by in vitro NIR Raman measurements on human cervical biopsies. Fluorescence spectra collected at 337, 380 and 460 nm excitation were used to develop a diagnostic method to differentiate between normal and dysplastic tissues. Using a fluorescence diagnostic method, a sensitivity and specificity of 80 % and 67 % were observed for differentiating squamous intraepithelial lesions (SILs) from all other tissues. In accordance with another aspect of the invention, using Raman scattering peaks observed at selected wavenumbers, SILs were separated from other tissues with a sensitivity and specificity of 88 % and 100 %. In addition, inflammation and metaplasia samples are correctly separated from the SILs.
Claims (37)
1. A method of detecting and quantifying tissue abnormality in a tissue sample, comprising:
illuminating said tissue sample with a first electromagnetic radiation wavelength selected to cause said tissue sample to produce a fluorescence intensity spectrum indicative of tissue abnormality;
detecting a first fluorescence intensity spectrum emitted from said tissue sample as a result of illumination with said first wavelength;
illuminating said tissue sample with a second electromagnetic radiation wavelength selected to cause said tissue sample to produce a fluorescence intensity spectrum indicative of a degree of tissue abnormality;
detecting a second fluorescence intensity spectrum emitted from said tissue sample as a result of illumination with said second wavelength;
calculating from said first fluorescence intensity spectrum, a probability that said tissue sample is normal or abnormal; and calculating from said second fluorescence intensity spectrum a degree of abnormality of said tissue sample.
illuminating said tissue sample with a first electromagnetic radiation wavelength selected to cause said tissue sample to produce a fluorescence intensity spectrum indicative of tissue abnormality;
detecting a first fluorescence intensity spectrum emitted from said tissue sample as a result of illumination with said first wavelength;
illuminating said tissue sample with a second electromagnetic radiation wavelength selected to cause said tissue sample to produce a fluorescence intensity spectrum indicative of a degree of tissue abnormality;
detecting a second fluorescence intensity spectrum emitted from said tissue sample as a result of illumination with said second wavelength;
calculating from said first fluorescence intensity spectrum, a probability that said tissue sample is normal or abnormal; and calculating from said second fluorescence intensity spectrum a degree of abnormality of said tissue sample.
2. The method of claim 1, each of said calculating steps comprising:
conducting principal component analysis of said first and second spectra, relative to a plurality of preprocessed spectra obtained from tissue samples of known diagnosis.
conducting principal component analysis of said first and second spectra, relative to a plurality of preprocessed spectra obtained from tissue samples of known diagnosis.
3. The method of claim 1, each of said calculating steps comprising:
normalizing said first and second spectra, relative to a maximum intensity within said spectra.
normalizing said first and second spectra, relative to a maximum intensity within said spectra.
4. The method of claim 3, each of said calculating steps further comprising:
mean-scaling said first and second spectra as a function of a mean intensity of said first and second spectra.
mean-scaling said first and second spectra as a function of a mean intensity of said first and second spectra.
5. A method of detecting tissue abnormality in a diagnostic tissue sample, comprising:
illuminating said tissue sample with an illumination wavelength of electromagnetic radiation selected to cause said tissue sample to emit a Raman spectrum comprising a plurality of wavelengths shifted from said illumination wavelength;
detecting a plurality of peak intensities of said Raman spectrum at wavelength shifts selected for their ability to distinguish normal tissue from abnormal tissue;
comparing each of said plurality of detected peak intensities at said wavelength shifts with intensities of a Raman spectrum from known normal tissue at corresponding wavelength shifts;
detecting abnormality of said tissue sample, as a function of said comparison.
illuminating said tissue sample with an illumination wavelength of electromagnetic radiation selected to cause said tissue sample to emit a Raman spectrum comprising a plurality of wavelengths shifted from said illumination wavelength;
detecting a plurality of peak intensities of said Raman spectrum at wavelength shifts selected for their ability to distinguish normal tissue from abnormal tissue;
comparing each of said plurality of detected peak intensities at said wavelength shifts with intensities of a Raman spectrum from known normal tissue at corresponding wavelength shifts;
detecting abnormality of said tissue sample, as a function of said comparison.
6. The method of claim 5, further comprising:
calculating a ratio between selected intensities of said Raman spectrum; and detecting abnormality of said tissue sample, as a function of said ratio
calculating a ratio between selected intensities of said Raman spectrum; and detecting abnormality of said tissue sample, as a function of said ratio
7. A method of detecting tissue abnormality in a diagnostic tissue sample, comprising:
illuminating said tissue sample with an illumination wavelength of electromagnetic radiation selected to cause said tissue sample to emit a Raman spectrum comprising a plurality of wavelengths shifted from said illumination wavelength;
detecting a plurality of peak intensities of said Raman spectrum at wavelength shifts selected by their ability to distinguish normal tissue from abnormal tissue;
calculating a ratio between at least two of said plurality of peak intensities; and detecting abnormality of said tissue sample, as a function of said ratio.
illuminating said tissue sample with an illumination wavelength of electromagnetic radiation selected to cause said tissue sample to emit a Raman spectrum comprising a plurality of wavelengths shifted from said illumination wavelength;
detecting a plurality of peak intensities of said Raman spectrum at wavelength shifts selected by their ability to distinguish normal tissue from abnormal tissue;
calculating a ratio between at least two of said plurality of peak intensities; and detecting abnormality of said tissue sample, as a function of said ratio.
8. The method of claim 7, further comprising:
calculating a second ratio between two of said plurality of peak intensities; and detecting a degree of tissue abnormality as a function of said second ratio.
calculating a second ratio between two of said plurality of peak intensities; and detecting a degree of tissue abnormality as a function of said second ratio.
9. A method of detecting tissue abnormality in a diagnostic tissue sample, comprising:
illuminating said tissue sample with electromagnetic radiation having a plurality of wavelengths, a first subset of said plurality of wavelengths having been selected to cause tissue to emit fluorescence spectra indicative of tissue abnormality, and a second set of said plurality of wavelengths having been selected to cause tissue to emit Raman spectra indicative of tissue abnormality;
detecting a fluorescence intensity spectrum from the tissue sample;
detecting a Raman spectrum from said tissue sample;
and assessing abnormality of said tissue sample as a function of said detected fluorescence spectrum and as a function of said detected Raman spectrum.
illuminating said tissue sample with electromagnetic radiation having a plurality of wavelengths, a first subset of said plurality of wavelengths having been selected to cause tissue to emit fluorescence spectra indicative of tissue abnormality, and a second set of said plurality of wavelengths having been selected to cause tissue to emit Raman spectra indicative of tissue abnormality;
detecting a fluorescence intensity spectrum from the tissue sample;
detecting a Raman spectrum from said tissue sample;
and assessing abnormality of said tissue sample as a function of said detected fluorescence spectrum and as a function of said detected Raman spectrum.
10. An apparatus for detecting and quantifying tissue abnormality in a tissue sample, comprising:
a controllable illumination source for emitting a plurality of electromagnetic radiation wavelengths selected to cause said tissue sample to produce fluorescence intensity spectra indicative of tissue abnormality;
an optical system coupled to said illumination source for applying said plurality of radiation wavelengths to a tissue sample;
a fluorescence intensity spectrum detecting device for detecting an intensity of fluorescence spectra emitted by said sample as a result of illumination by said plurality of electromagnetic radiation wavelengths;
a data processor, connected to said detecting device, for analyzing detected fluorescence spectra to calculate a probability that said sample is abnormal.
a controllable illumination source for emitting a plurality of electromagnetic radiation wavelengths selected to cause said tissue sample to produce fluorescence intensity spectra indicative of tissue abnormality;
an optical system coupled to said illumination source for applying said plurality of radiation wavelengths to a tissue sample;
a fluorescence intensity spectrum detecting device for detecting an intensity of fluorescence spectra emitted by said sample as a result of illumination by said plurality of electromagnetic radiation wavelengths;
a data processor, connected to said detecting device, for analyzing detected fluorescence spectra to calculate a probability that said sample is abnormal.
11. A Raman spectroscopy apparatus for detecting tissue abnormality in a tissue sample, comprising:
a controllable illumination device for generating at least one illumination wavelength of electromagnetic radiation selected to cause a tissue sample to emit a Raman spectrum including a plurality of wavelengths shifted from said illumination wavelength;
a Raman spectrum detector for detecting a plurality of peak intensities of said Raman spectrum at selected wavelength shifts; and a programmed computer connected to said Raman spectrum detector, programmed to compare each of said plurality of detected peak intensities with corresponding peak intensities of a Raman spectrum from known normal tissue, to detect tissue abnormality.
- 62 -
a controllable illumination device for generating at least one illumination wavelength of electromagnetic radiation selected to cause a tissue sample to emit a Raman spectrum including a plurality of wavelengths shifted from said illumination wavelength;
a Raman spectrum detector for detecting a plurality of peak intensities of said Raman spectrum at selected wavelength shifts; and a programmed computer connected to said Raman spectrum detector, programmed to compare each of said plurality of detected peak intensities with corresponding peak intensities of a Raman spectrum from known normal tissue, to detect tissue abnormality.
- 62 -
12. An apparatus for detecting and classifying tissue abnormality at a tissue site, comprising:
a first source of electromagnetic radiation of a first wavelength that excites different first fluorescence intensity spectra in normal and abnormal tissue;
a first receiver sensitive to the first fluorescence intensity spectra;
means coupled to the first receiver for calculating from the first fluorescence intensity spectra a first probability that the tissue site is normal or abnormal;
a second source of electromagnetic radiation of a second wavelength that excites different second fluorescence intensity spectra in tissues having different types of abnormality a second receiver sensitive to the second fluorescence intensity spectra;
means coupled to the second receiver and to the first probability calculating means for calculating from the second fluorescence intensity spectra a second probability that the tissue site is of a particular type of abnormality, when the first probability is indicative of abnormality at the tissue site;
and a tissue site probe coupled to the first and second sources and to the first and second receivers.
a first source of electromagnetic radiation of a first wavelength that excites different first fluorescence intensity spectra in normal and abnormal tissue;
a first receiver sensitive to the first fluorescence intensity spectra;
means coupled to the first receiver for calculating from the first fluorescence intensity spectra a first probability that the tissue site is normal or abnormal;
a second source of electromagnetic radiation of a second wavelength that excites different second fluorescence intensity spectra in tissues having different types of abnormality a second receiver sensitive to the second fluorescence intensity spectra;
means coupled to the second receiver and to the first probability calculating means for calculating from the second fluorescence intensity spectra a second probability that the tissue site is of a particular type of abnormality, when the first probability is indicative of abnormality at the tissue site;
and a tissue site probe coupled to the first and second sources and to the first and second receivers.
13. An apparatus as in claim 12 wherein the first probability calculating means comprises:
means for conducting a first principle component analysis of the first fluorescence intensity spectra; and means coupled to the first principle component analysis means for conducting a logistic discriminant analysis to obtain the first probability;
and wherein the second probability calculating means comprises:
means for conducting a second principle component analysis of the second fluorescence intensity spectra; and means coupled to the second principle component analysis means for conducting a logistic discriminant analysis to obtain the second probability.
means for conducting a first principle component analysis of the first fluorescence intensity spectra; and means coupled to the first principle component analysis means for conducting a logistic discriminant analysis to obtain the first probability;
and wherein the second probability calculating means comprises:
means for conducting a second principle component analysis of the second fluorescence intensity spectra; and means coupled to the second principle component analysis means for conducting a logistic discriminant analysis to obtain the second probability.
14. An apparatus as in claim 13 wherein:
the first probability calculating means further comprises means for normalizing the first fluorescence intensity spectra relative to respective maximum intensities thereof, prior to conducting the first principle component analysis in the first principle, component analysis means; and the second probability calculating means further comprises means for normalizing the second fluorescence intensity spectra relative to respective maximum intensities thereof, prior to conducting the second principle component analysis in the second principle component analysis means.
the first probability calculating means further comprises means for normalizing the first fluorescence intensity spectra relative to respective maximum intensities thereof, prior to conducting the first principle component analysis in the first principle, component analysis means; and the second probability calculating means further comprises means for normalizing the second fluorescence intensity spectra relative to respective maximum intensities thereof, prior to conducting the second principle component analysis in the second principle component analysis means.
15. An apparatus as in claim 13 wherein:
the first probability calculating means further comprises means for mean-scaling the first fluorescence intensity spectra as a function of a mean intensity thereof, prior to conducting the first principle component analysis in the first principle component analysis means; and the second probability calculating means further comprises means for mean-scaling the second fluorescence intensity spectra as a function of a mean intensity thereof, prior to conducting the second principle component analysis in the second principle component analysis means.
the first probability calculating means further comprises means for mean-scaling the first fluorescence intensity spectra as a function of a mean intensity thereof, prior to conducting the first principle component analysis in the first principle component analysis means; and the second probability calculating means further comprises means for mean-scaling the second fluorescence intensity spectra as a function of a mean intensity thereof, prior to conducting the second principle component analysis in the second principle component analysis means.
16. An apparatus as in claim 12 wherein:
the first and second sources comprise a pulsed nitrogen pumped dye laser respectively operated to generate pulses at the first wavelength having a power level, pulse duration, and repetition rate that excite the first fluorescence intensity spectra in normal and abnormal tissue, and to generate pulses at the second wavelength having a power level, pulse duration, and repetition rate that excite the second fluorescence intensity spectra in tissues having different types of abnormality;
and the first and second receivers comprise a polychromator coupled to an intensified diode array controlled by a multi-channel analyzer, respectively synchronized to the first and second sources.
the first and second sources comprise a pulsed nitrogen pumped dye laser respectively operated to generate pulses at the first wavelength having a power level, pulse duration, and repetition rate that excite the first fluorescence intensity spectra in normal and abnormal tissue, and to generate pulses at the second wavelength having a power level, pulse duration, and repetition rate that excite the second fluorescence intensity spectra in tissues having different types of abnormality;
and the first and second receivers comprise a polychromator coupled to an intensified diode array controlled by a multi-channel analyzer, respectively synchronized to the first and second sources.
17. An apparatus for detecting and classifying tissue abnormality at a tissue site, comprising:
a controllable illumination source for emitting a plurality of electromagnetic radiation wavelengths selected to cause tissue to produce fluorescence intensity spectra indicative of tissue abnormality;
an optical system coupled to the illumination source for applying the plurality of electromagnetic radiation wavelengths to the tissue site;
a fluorescence intensity spectrum detecting device for detecting an intensity of fluorescence spectra emitted by the tissue site as a result of illumination by the plurality of electromagnetic radiation wavelengths; and a first data processor coupled to the detecting device for calculating from the detected fluorescence intensity spectra a probability that the tissue site contains a particular type of abnormal tissue.
a controllable illumination source for emitting a plurality of electromagnetic radiation wavelengths selected to cause tissue to produce fluorescence intensity spectra indicative of tissue abnormality;
an optical system coupled to the illumination source for applying the plurality of electromagnetic radiation wavelengths to the tissue site;
a fluorescence intensity spectrum detecting device for detecting an intensity of fluorescence spectra emitted by the tissue site as a result of illumination by the plurality of electromagnetic radiation wavelengths; and a first data processor coupled to the detecting device for calculating from the detected fluorescence intensity spectra a probability that the tissue site contains a particular type of abnormal tissue.
18. A method for detecting and classifying tissue abnormality in a tissue site, comprising:
applying a plurality of electromagnetic radiation wavelengths to a tissue site to cause the tissue site to produce fluorescence intensity spectra indicative of tissue abnormality;
detecting an intensity of the fluorescence spectra emitted by said site as a result of illumination by said plurality of electromagnetic radiation wavelengths; and calculating from the detected fluorescence spectra a probability that said tissue site contains a particular type of abnormal tissue.
applying a plurality of electromagnetic radiation wavelengths to a tissue site to cause the tissue site to produce fluorescence intensity spectra indicative of tissue abnormality;
detecting an intensity of the fluorescence spectra emitted by said site as a result of illumination by said plurality of electromagnetic radiation wavelengths; and calculating from the detected fluorescence spectra a probability that said tissue site contains a particular type of abnormal tissue.
19. A method of detecting and classifying abnormal tissue at a tissue site of a patient, comprising:
applying electromagnetic radiation to the tissue site at a first wavelength that excites different fluorescence intensity spectra within a first wavelength range in normal and abnormal tissue;
applying electromagnetic radiation to the tissue site at a second wavelength that excites different fluorescence intensity spectra within a second wavelength range in tissues having different types of dysplasia;
obtaining measurements of fluorescence intensities from the first wavelength and second wavelength applying steps within the first and second wavelength ranges;
calculating from the measurements of fluorescence intensities a first probability that the tissue site is normal or abnormal and a second probability that the tissue site is of a particular type of dysplasia; and classifying the tissue site as normal or abnormal and if abnormal, as to as to type of dysplasia, in accordance with the first and second probabilities.
applying electromagnetic radiation to the tissue site at a first wavelength that excites different fluorescence intensity spectra within a first wavelength range in normal and abnormal tissue;
applying electromagnetic radiation to the tissue site at a second wavelength that excites different fluorescence intensity spectra within a second wavelength range in tissues having different types of dysplasia;
obtaining measurements of fluorescence intensities from the first wavelength and second wavelength applying steps within the first and second wavelength ranges;
calculating from the measurements of fluorescence intensities a first probability that the tissue site is normal or abnormal and a second probability that the tissue site is of a particular type of dysplasia; and classifying the tissue site as normal or abnormal and if abnormal, as to as to type of dysplasia, in accordance with the first and second probabilities.
20. A method as in claim 19 wherein the calculating step comprises:
preprocessing the measurements of fluorescence intensities within the first wavelength range to remove known and diagnostically immaterial variations therefrom;
applying a first set of orthogonal elements that account for diagnostically significant differences between different fluorescence intensity spectra within the first wavelength range of normal and abnormal tissue in a population inclusive of the patient, to the preprocessed measurements of fluorescence intensities within the first wavelength range, to obtain first scores for the tissue site;
calculating the first probability based on the first site scores;
preprocessing the measurements of fluorescence intensities within the second wavelength range to remove known and diagnostically immaterial variations therefrom;
applying a second set of orthogonal elements that account for diagnostically significant differences between different fluorescence intensity spectra within the second wavelength range of normal and abnormal tissue in a population inclusive of the patient, to the preprocessed measurements of fluorescence intensities within the second wavelength range, to obtain second scores for the tissue site;
and calculating the second probability based on the second site scores.
preprocessing the measurements of fluorescence intensities within the first wavelength range to remove known and diagnostically immaterial variations therefrom;
applying a first set of orthogonal elements that account for diagnostically significant differences between different fluorescence intensity spectra within the first wavelength range of normal and abnormal tissue in a population inclusive of the patient, to the preprocessed measurements of fluorescence intensities within the first wavelength range, to obtain first scores for the tissue site;
calculating the first probability based on the first site scores;
preprocessing the measurements of fluorescence intensities within the second wavelength range to remove known and diagnostically immaterial variations therefrom;
applying a second set of orthogonal elements that account for diagnostically significant differences between different fluorescence intensity spectra within the second wavelength range of normal and abnormal tissue in a population inclusive of the patient, to the preprocessed measurements of fluorescence intensities within the second wavelength range, to obtain second scores for the tissue site;
and calculating the second probability based on the second site scores.
21. A method as in claim 20 wherein:
the first set of orthogonal elements is a set of principal components;
the first scores for the orthogonal elements are principal component scores;
the second set of orthogonal elements is a set of principal components; and the second scores for the orthogonal elements are principal component scores.
the first set of orthogonal elements is a set of principal components;
the first scores for the orthogonal elements are principal component scores;
the second set of orthogonal elements is a set of principal components; and the second scores for the orthogonal elements are principal component scores.
22. A method as in claim 20 further comprising generating the first and second sets of orthogonal elements, wherein the step of generating the first set of orthogonal elements comprises:
selecting a training set comprising a plurality of subjects having a known distribution of normal and histo-pathological tissue types for tissue morphologically similar to the tissue site;
applying electromagnetic radiation at the first wavelength to the tissue of the training set;
measuring first training fluorescence intensities within the first wavelength range resulting from the step of applying electromagnetic radiation to the tissue of the training set;
preprocessing the first training fluorescence intensities to remove known and diagnostically immaterial variations therefrom; and transforming the normalized measurements of first training fluorescence intensities into the first set of orthogonal elements, wherein the first set of orthogonal elements is limited to diagnostically useful orthogonal elements that account for significant variations between the normalized measurements of first training fluorescence intensities in the normal and histo-pathological tissue types;
and wherein the step of generating the second set of orthogonal elements comprises:
applying electromagnetic radiation at the second wavelength to the tissue of the training set;
measuring second training fluorescence intensities within the second wavelength range resulting from the step of applying electromagnetic radiation to the tissue of the training set;
preprocessing the second training fluorescence intensities to remove known and diagnostically immaterial variations therefrom; and transforming the second normalized measurements of training fluorescence intensities into the second set of orthogonal elements, wherein the second set of orthogonal elements is limited to diagnostically useful orthogonal elements that account for significant variations between the normalized measurements of second training fluorescence intensities in the histo-pathological tissue types.
selecting a training set comprising a plurality of subjects having a known distribution of normal and histo-pathological tissue types for tissue morphologically similar to the tissue site;
applying electromagnetic radiation at the first wavelength to the tissue of the training set;
measuring first training fluorescence intensities within the first wavelength range resulting from the step of applying electromagnetic radiation to the tissue of the training set;
preprocessing the first training fluorescence intensities to remove known and diagnostically immaterial variations therefrom; and transforming the normalized measurements of first training fluorescence intensities into the first set of orthogonal elements, wherein the first set of orthogonal elements is limited to diagnostically useful orthogonal elements that account for significant variations between the normalized measurements of first training fluorescence intensities in the normal and histo-pathological tissue types;
and wherein the step of generating the second set of orthogonal elements comprises:
applying electromagnetic radiation at the second wavelength to the tissue of the training set;
measuring second training fluorescence intensities within the second wavelength range resulting from the step of applying electromagnetic radiation to the tissue of the training set;
preprocessing the second training fluorescence intensities to remove known and diagnostically immaterial variations therefrom; and transforming the second normalized measurements of training fluorescence intensities into the second set of orthogonal elements, wherein the second set of orthogonal elements is limited to diagnostically useful orthogonal elements that account for significant variations between the normalized measurements of second training fluorescence intensities in the histo-pathological tissue types.
23. A method as in claim 22 further comprising:
calculating first training scores for the first set of orthogonal elements from the first training fluorescence intensities;
generating first probability distributions of the first training scores for each of the normal and histo-pathological tissue types;
calculating second training scores for the second set of orthogonal elements from the second training fluorescence intensities; and generating second probability distributions of the second training scores for each of the histo-pathological tissue types; and obtaining prior probabilities based on the training set;
wherein the first probability calculating step comprises:
developing from the first probability distributions first conditional joint probabilities that the normal and histo-pathological tissue types of the training set will exhibit the first site scores; and calculating the first probability as posterior probabilities of normality and abnormality for the tissue site from the first conditional joint probabilities and the prior probabilities;
and wherein the second probability calculating step comprises:
developing from the second probability distributions second conditional joint probabilities that the histo-pathological tissue types of the training set will exhibit the second site scores; and calculating the second probability as posterior probabilities of the type of histo-pathological tissue for the tissue site from the second conditional joint probabilities and the prior probabilities.
calculating first training scores for the first set of orthogonal elements from the first training fluorescence intensities;
generating first probability distributions of the first training scores for each of the normal and histo-pathological tissue types;
calculating second training scores for the second set of orthogonal elements from the second training fluorescence intensities; and generating second probability distributions of the second training scores for each of the histo-pathological tissue types; and obtaining prior probabilities based on the training set;
wherein the first probability calculating step comprises:
developing from the first probability distributions first conditional joint probabilities that the normal and histo-pathological tissue types of the training set will exhibit the first site scores; and calculating the first probability as posterior probabilities of normality and abnormality for the tissue site from the first conditional joint probabilities and the prior probabilities;
and wherein the second probability calculating step comprises:
developing from the second probability distributions second conditional joint probabilities that the histo-pathological tissue types of the training set will exhibit the second site scores; and calculating the second probability as posterior probabilities of the type of histo-pathological tissue for the tissue site from the second conditional joint probabilities and the prior probabilities.
24. A method of classifying a cervical tissue site as normal or of a particular histo-pathological type based on autofluorescence, comprising:
selecting a training set comprising a plurality of subjects having a known distribution of normal and histo-pathological cervical tissue types;
applying electromagnetic radiation at plural excitation wavelengths to excite fluorescence in the various normal and histo-pathological tissue types of the training set;
detecting sets of training fluorescence intensity spectra respectively excited in the various normal and histo-pathological tissue types of the training set at the plural excitation wavelengths;
preprocessing the training fluorescence intensity spectra to remove known and diagnostically immaterial variations therefrom;
transforming the sets of preprocessed training fluorescence intensity spectra for each of the plural excitation wavelengths into a set of principal components that account for significant variations therein;
limiting the sets of principal components to diagnostically useful principal components for each of the plural excitation wavelengths in accordance with the known distribution of normal and histo-pathological tissue types;
calculating respective training scores for the limited sets of principal components from the preprocessed training fluorescence intensity spectra;
generating probability distributions of the calculated training principal component scores for each of the normal and histo-pathological tissue types;
applying electromagnetic radiation at the plural excitation wavelengths to excite fluorescence in the cervical tissue site;
detecting first and second fluorescence intensity spectra excited in the cervical tissue site at the plural excitation wavelengths;
preprocessing the first and second fluorescence intensity spectra to remove known and diagnostically immaterial variations therefrom;
calculating first and second scores for the limited sets of principal components based on the first and second fluorescence spectra;
developing from the probability distributions first and second conditional joint probabilities that the various normal and histo-pathological tissue types of the training set will exhibit the first and second principal component scores;
obtaining prior probabilities based on the training set;
calculating posterior probabilities of normality and abnormality for the cervical tissue site from the first conditional joint probabilities and the prior probabilities;
classifying the cervical site as normal or abnormal based on which of the posterior probabilities of normality and abnormality is highest;
calculating posterior probabilities of type of histo-pathological abnormality for the cervical tissue site from the second conditional joint probabilities and the prior probabilities; and where the cervical site is classified as abnormal in the normal or abnormal classifying step, classifying the cervical site as to type of type of histo-pathological abnormality based on which of the posterior probabilities of type of histo-pathological abnormality is highest.
selecting a training set comprising a plurality of subjects having a known distribution of normal and histo-pathological cervical tissue types;
applying electromagnetic radiation at plural excitation wavelengths to excite fluorescence in the various normal and histo-pathological tissue types of the training set;
detecting sets of training fluorescence intensity spectra respectively excited in the various normal and histo-pathological tissue types of the training set at the plural excitation wavelengths;
preprocessing the training fluorescence intensity spectra to remove known and diagnostically immaterial variations therefrom;
transforming the sets of preprocessed training fluorescence intensity spectra for each of the plural excitation wavelengths into a set of principal components that account for significant variations therein;
limiting the sets of principal components to diagnostically useful principal components for each of the plural excitation wavelengths in accordance with the known distribution of normal and histo-pathological tissue types;
calculating respective training scores for the limited sets of principal components from the preprocessed training fluorescence intensity spectra;
generating probability distributions of the calculated training principal component scores for each of the normal and histo-pathological tissue types;
applying electromagnetic radiation at the plural excitation wavelengths to excite fluorescence in the cervical tissue site;
detecting first and second fluorescence intensity spectra excited in the cervical tissue site at the plural excitation wavelengths;
preprocessing the first and second fluorescence intensity spectra to remove known and diagnostically immaterial variations therefrom;
calculating first and second scores for the limited sets of principal components based on the first and second fluorescence spectra;
developing from the probability distributions first and second conditional joint probabilities that the various normal and histo-pathological tissue types of the training set will exhibit the first and second principal component scores;
obtaining prior probabilities based on the training set;
calculating posterior probabilities of normality and abnormality for the cervical tissue site from the first conditional joint probabilities and the prior probabilities;
classifying the cervical site as normal or abnormal based on which of the posterior probabilities of normality and abnormality is highest;
calculating posterior probabilities of type of histo-pathological abnormality for the cervical tissue site from the second conditional joint probabilities and the prior probabilities; and where the cervical site is classified as abnormal in the normal or abnormal classifying step, classifying the cervical site as to type of type of histo-pathological abnormality based on which of the posterior probabilities of type of histo-pathological abnormality is highest.
25. A method as in claim 24 wherein the cervical tissue site is in vivo.
26. A method as in claim 24 wherein the cervical tissue site is in vitro.
27. A method of identifying a set of orthogonal elements to score based on a measurement of tissue fluorescence intensities from a site of unknown tissue, and obtaining probability distributions of scores from which a probability that the unknown tissue is a particular type of tissue may be calculated, comprising:
selecting a training set comprising a plurality of subjects having a known distribution of tissue types for tissue morphologically similar to the unknown tissue;
applying electromagnetic radiation that excites different fluorescence intensity amplitudes within a range of wavelengths in the tissue types of the training set;
measuring fluorescence intensities resulting from the step of applying electromagnetic radiation to the tissue of the training set;
preprocessing the measured fluorescence intensities to remove known and diagnostically immaterial variations therefrom;
transforming the preprocessed measurements of fluorescence intensities into a set of orthogonal elements that account for significant variations between the preprocessed fluorescence intensities from the tissue types;
limiting the set of orthogonal elements to diagnostically useful orthogonal elements in accordance with the known distribution of the tissue types;
calculating scores for the limited set of orthogonal elements; and generating probability distributions of the calculated scores for each of the tissue types.
selecting a training set comprising a plurality of subjects having a known distribution of tissue types for tissue morphologically similar to the unknown tissue;
applying electromagnetic radiation that excites different fluorescence intensity amplitudes within a range of wavelengths in the tissue types of the training set;
measuring fluorescence intensities resulting from the step of applying electromagnetic radiation to the tissue of the training set;
preprocessing the measured fluorescence intensities to remove known and diagnostically immaterial variations therefrom;
transforming the preprocessed measurements of fluorescence intensities into a set of orthogonal elements that account for significant variations between the preprocessed fluorescence intensities from the tissue types;
limiting the set of orthogonal elements to diagnostically useful orthogonal elements in accordance with the known distribution of the tissue types;
calculating scores for the limited set of orthogonal elements; and generating probability distributions of the calculated scores for each of the tissue types.
28. A method of identifying a set of orthogonal principal components to score based on a measurement of tissue fluorescence intensities from a site of unknown tissue, and obtaining probability distributions of principal component scores from which a probability that the unknown tissue is of a particular type, either normal or abnormal or of a particular histo-pathological type, may be calculated, comprising:
selecting a training set comprising a plurality of subjects having a known distribution of tissue types in tissue sites for tissue morphologically similar to the unknown tissue;
applying to the tissue sites electromagnetic radiation that excites different fluorescence intensity amplitudes within a range of wavelengths in the tissue types of the training set;
measuring fluorescence intensities resulting from the step of applying electromagnetic radiation to the tissue sites;
preprocessing the measured fluorescence intensities to remove known and diagnostically immaterial variations therefrom;
transforming the preprocessed measurements of fluorescence intensities into a set of principal components that account for significant variations between the preprocessed fluorescence intensities from the tissue types;
limiting the set of principal components to diagnostically useful principal components in accordance with the known distribution of tissue types;
calculating scores for the limited set of principal components; and generating probability distributions of the calculated principal component scores for each of the tissue types.
selecting a training set comprising a plurality of subjects having a known distribution of tissue types in tissue sites for tissue morphologically similar to the unknown tissue;
applying to the tissue sites electromagnetic radiation that excites different fluorescence intensity amplitudes within a range of wavelengths in the tissue types of the training set;
measuring fluorescence intensities resulting from the step of applying electromagnetic radiation to the tissue sites;
preprocessing the measured fluorescence intensities to remove known and diagnostically immaterial variations therefrom;
transforming the preprocessed measurements of fluorescence intensities into a set of principal components that account for significant variations between the preprocessed fluorescence intensities from the tissue types;
limiting the set of principal components to diagnostically useful principal components in accordance with the known distribution of tissue types;
calculating scores for the limited set of principal components; and generating probability distributions of the calculated principal component scores for each of the tissue types.
29. A method as in claim 28 wherein.
the applied electromagnetic radiation has a wavelength of 337 nm;
the tissue morphology is cervical tissue and the tissue types are squamous normal, columnar normal, low grade squamous intraepithelial lesions, and high grade squamous intraepithelial lesions; and the set of principal components is limited to principal components that demonstrate the statistically most significant differences between normal squamous epithelia and low and high grade squamous intraepithelial lesions.
the applied electromagnetic radiation has a wavelength of 337 nm;
the tissue morphology is cervical tissue and the tissue types are squamous normal, columnar normal, low grade squamous intraepithelial lesions, and high grade squamous intraepithelial lesions; and the set of principal components is limited to principal components that demonstrate the statistically most significant differences between normal squamous epithelia and low and high grade squamous intraepithelial lesions.
30. A method as in claim 28 wherein:
the applied electromagnetic radiation has a wavelength of 380 nm;
the tissue morphology is cervical tissue and the tissue types are squamous normal, columnar normal, low grade squamous intraepithelial lesions, and high grade squamous intraepithelial lesions; and the set of principal components is limited to principal components that demonstrate the statistically most significant differences between normal columnar epithelia and low and high grade squamous intraepithelial lesions.
the applied electromagnetic radiation has a wavelength of 380 nm;
the tissue morphology is cervical tissue and the tissue types are squamous normal, columnar normal, low grade squamous intraepithelial lesions, and high grade squamous intraepithelial lesions; and the set of principal components is limited to principal components that demonstrate the statistically most significant differences between normal columnar epithelia and low and high grade squamous intraepithelial lesions.
31. A method as in claim 28 wherein:
the applied electromagnetic radiation has a wavelength of 460 nm;
the tissue morphology is cervical tissue and the tissue types are squamous normal, columnar normal, low grade squamous intraepithelial lesions, and high grade squamous intraepithelial lesions; and the set of principal components is limited to principal components that demonstrate the statistically most significant differences between low grade squamous intraepithelial lesions and high grade squamous intraepithelial lesions.
the applied electromagnetic radiation has a wavelength of 460 nm;
the tissue morphology is cervical tissue and the tissue types are squamous normal, columnar normal, low grade squamous intraepithelial lesions, and high grade squamous intraepithelial lesions; and the set of principal components is limited to principal components that demonstrate the statistically most significant differences between low grade squamous intraepithelial lesions and high grade squamous intraepithelial lesions.
32. A method as in claim 28 wherein the preprocessing step comprises normalizing the measured fluorescence intensities for each of the tissue sites within the range of wavelengths to a peak intensity of one.
33. A method as in claim 28 wherein the preprocessing step comprises:
calculating a mean spectrum for each subject from the measured fluorescence intensities of the tissue sites of said each subject within the range of wavelengths therefor; and subtracting the mean spectrum for said each subject from the measured fluorescence intensities of the tissue sites of said each subject within the range of wavelengths therefor.
calculating a mean spectrum for each subject from the measured fluorescence intensities of the tissue sites of said each subject within the range of wavelengths therefor; and subtracting the mean spectrum for said each subject from the measured fluorescence intensities of the tissue sites of said each subject within the range of wavelengths therefor.
34. A method in claim 28 wherein the transforming step comprises:
forming a data matrix D from the fluorescence intensities;
calculating a covariance matrix Z from the matrix D
in accordance with the expression calculating a variance V accounted for by the first Z = n eigenvalues in accordance with the expression retaining eigenvalues and corresponding eigenvectors in a matrix C that account for 99% of the variance V.
forming a data matrix D from the fluorescence intensities;
calculating a covariance matrix Z from the matrix D
in accordance with the expression calculating a variance V accounted for by the first Z = n eigenvalues in accordance with the expression retaining eigenvalues and corresponding eigenvectors in a matrix C that account for 99% of the variance V.
35. A method as in claim 34 wherein the transforming step further comprises:
calculating, component loadings C for each of the principal components in accordance with the expression CLij = eliminating fluorescence intensities at wavelengths within the range of wavelengths that are not most highly correlated with the component loadings, prior to the limited step.
calculating, component loadings C for each of the principal components in accordance with the expression CLij = eliminating fluorescence intensities at wavelengths within the range of wavelengths that are not most highly correlated with the component loadings, prior to the limited step.
36. A method as in claim 34 wherein the limited step comprises:
calculating a principal component score matrix R in accordance with the expression R = D x C; and calculating a diagnostic contribution of each principal component from the matrix R using a two-sided unpaired student's t-test.
calculating a principal component score matrix R in accordance with the expression R = D x C; and calculating a diagnostic contribution of each principal component from the matrix R using a two-sided unpaired student's t-test.
37. A method as in claim 36 wherein the probability distributions generating step comprises modeling the probability distributions using a gamma function defined by the expression f(x;.alpha.,.beta.) =
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/403,446 | 1995-03-14 | ||
| US08/403,446 US5697373A (en) | 1995-03-14 | 1995-03-14 | Optical method and apparatus for the diagnosis of cervical precancers using raman and fluorescence spectroscopies |
| PCT/US1996/002644 WO1996028084A1 (en) | 1995-03-14 | 1996-03-08 | Optical method and apparatus for the diagnosis of cervical precancers using raman and fluorescence spectroscopies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2190374A1 true CA2190374A1 (en) | 1996-09-19 |
| CA2190374C CA2190374C (en) | 2010-07-13 |
Family
ID=23595799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2190374A Expired - Fee Related CA2190374C (en) | 1995-03-14 | 1996-03-08 | Optical method and apparatus for the diagnosis of cervical precancers using raman and fluorescence spectroscopies |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US5697373A (en) |
| EP (1) | EP0765134B1 (en) |
| JP (1) | JPH10505167A (en) |
| CA (1) | CA2190374C (en) |
| DE (1) | DE69637163T2 (en) |
| WO (1) | WO1996028084A1 (en) |
Families Citing this family (304)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6564087B1 (en) | 1991-04-29 | 2003-05-13 | Massachusetts Institute Of Technology | Fiber optic needle probes for optical coherence tomography imaging |
| US6485413B1 (en) | 1991-04-29 | 2002-11-26 | The General Hospital Corporation | Methods and apparatus for forward-directed optical scanning instruments |
| US6111645A (en) | 1991-04-29 | 2000-08-29 | Massachusetts Institute Of Technology | Grating based phase control optical delay line |
| US5590660A (en) * | 1994-03-28 | 1997-01-07 | Xillix Technologies Corp. | Apparatus and method for imaging diseased tissue using integrated autofluorescence |
| US5991653A (en) * | 1995-03-14 | 1999-11-23 | Board Of Regents, The University Of Texas System | Near-infrared raman spectroscopy for in vitro and in vivo detection of cervical precancers |
| US7236815B2 (en) * | 1995-03-14 | 2007-06-26 | The Board Of Regents Of The University Of Texas System | Method for probabilistically classifying tissue in vitro and in vivo using fluorescence spectroscopy |
| US6258576B1 (en) | 1996-06-19 | 2001-07-10 | Board Of Regents, The University Of Texas System | Diagnostic method and apparatus for cervical squamous intraepithelial lesions in vitro and in vivo using fluorescence spectroscopy |
| US5735276A (en) * | 1995-03-21 | 1998-04-07 | Lemelson; Jerome | Method and apparatus for scanning and evaluating matter |
| US20010041843A1 (en) * | 1999-02-02 | 2001-11-15 | Mark Modell | Spectral volume microprobe arrays |
| US6031232A (en) * | 1995-11-13 | 2000-02-29 | Bio-Rad Laboratories, Inc. | Method for the detection of malignant and premalignant stages of cervical cancer |
| US6174424B1 (en) | 1995-11-20 | 2001-01-16 | Cirrex Corp. | Couplers for optical fibers |
| US5953477A (en) | 1995-11-20 | 1999-09-14 | Visionex, Inc. | Method and apparatus for improved fiber optic light management |
| US5902246A (en) | 1996-03-26 | 1999-05-11 | Lifespex, Incorporated | Method and apparatus for calibrating an optical probe |
| CA2264870C (en) * | 1996-08-02 | 2005-07-26 | Board Of Regents, The University Of Texas System | Apparatus for the characterization of tissue of epithelial lined viscus |
| DE19640495C2 (en) * | 1996-10-01 | 1999-12-16 | Leica Microsystems | Device for confocal surface measurement |
| US6135965A (en) * | 1996-12-02 | 2000-10-24 | Board Of Regents, The University Of Texas System | Spectroscopic detection of cervical pre-cancer using radial basis function networks |
| US6826422B1 (en) | 1997-01-13 | 2004-11-30 | Medispectra, Inc. | Spectral volume microprobe arrays |
| US6201989B1 (en) | 1997-03-13 | 2001-03-13 | Biomax Technologies Inc. | Methods and apparatus for detecting the rejection of transplanted tissue |
| US6208783B1 (en) | 1997-03-13 | 2001-03-27 | Cirrex Corp. | Optical filtering device |
| US6008889A (en) * | 1997-04-16 | 1999-12-28 | Zeng; Haishan | Spectrometer system for diagnosis of skin disease |
| US6081740A (en) * | 1997-04-23 | 2000-06-27 | Accumed International, Inc. | Method and apparatus for imaging and sampling diseased tissue |
| US5999844A (en) * | 1997-04-23 | 1999-12-07 | Accumed International, Inc. | Method and apparatus for imaging and sampling diseased tissue using autofluorescence |
| US7206623B2 (en) | 2000-05-02 | 2007-04-17 | Sensys Medical, Inc. | Optical sampling interface system for in vivo measurement of tissue |
| US7383069B2 (en) | 1997-08-14 | 2008-06-03 | Sensys Medical, Inc. | Method of sample control and calibration adjustment for use with a noninvasive analyzer |
| US6091984A (en) | 1997-10-10 | 2000-07-18 | Massachusetts Institute Of Technology | Measuring tissue morphology |
| CN1302210A (en) * | 1997-10-20 | 2001-07-04 | 得克萨斯系统大学评议会 | Acetic acid as a signal enhancing contrast agent in fluorescence spectroscopy |
| US6937885B1 (en) * | 1997-10-30 | 2005-08-30 | Hypermed, Inc. | Multispectral/hyperspectral medical instrument |
| US6055451A (en) | 1997-12-12 | 2000-04-25 | Spectrx, Inc. | Apparatus and method for determining tissue characteristics |
| US6091985A (en) * | 1998-01-23 | 2000-07-18 | Research Foundation Of City College Of New York | Detection of cancer and precancerous conditions in tissues and/or cells using native fluorescence excitation spectroscopy |
| SE9801420D0 (en) * | 1998-04-22 | 1998-04-22 | Mikael Kubista | Method for characterizing individual test samples |
| US6389306B1 (en) * | 1998-04-24 | 2002-05-14 | Lightouch Medical, Inc. | Method for determining lipid and protein content of tissue |
| US6466894B2 (en) * | 1998-06-18 | 2002-10-15 | Nec Corporation | Device, method, and medium for predicting a probability of an occurrence of a data |
| GB9815701D0 (en) * | 1998-07-21 | 1998-09-16 | Cambridge Imaging Ltd | Improved imaging system for fluorescence assays |
| EP1112022A4 (en) * | 1998-09-11 | 2004-08-04 | Spectrx Inc | Multi-modal optical tissue diagnostic system |
| US6377842B1 (en) | 1998-09-22 | 2002-04-23 | Aurora Optics, Inc. | Method for quantitative measurement of fluorescent and phosphorescent drugs within tissue utilizing a fiber optic probe |
| US6678541B1 (en) | 1998-10-28 | 2004-01-13 | The Governmemt Of The United States Of America | Optical fiber probe and methods for measuring optical properties |
| DE19854292C2 (en) * | 1998-11-19 | 2000-11-30 | Werner Schramm | Method and arrangement for multiparametric diagnosis of biological tissue |
| US6411838B1 (en) * | 1998-12-23 | 2002-06-25 | Medispectra, Inc. | Systems and methods for optical examination of samples |
| US6404497B1 (en) | 1999-01-25 | 2002-06-11 | Massachusetts Institute Of Technology | Polarized light scattering spectroscopy of tissue |
| US6580935B1 (en) | 1999-03-12 | 2003-06-17 | Cirrex Corp. | Method and system for stabilizing reflected light |
| US20020058028A1 (en) * | 1999-05-05 | 2002-05-16 | Mark K. Malmros | Method of in situ diagnosis by spectroscopic analysis of biological stain compositions |
| US6167297A (en) * | 1999-05-05 | 2000-12-26 | Benaron; David A. | Detecting, localizing, and targeting internal sites in vivo using optical contrast agents |
| US6424859B2 (en) * | 1999-06-17 | 2002-07-23 | Michael Jackson | Diagnosis of rheumatoid arthritis in vivo using a novel spectroscopic approach |
| US6205354B1 (en) * | 1999-06-18 | 2001-03-20 | University Of Utah | Method and apparatus for noninvasive measurement of carotenoids and related chemical substances in biological tissue |
| US6697666B1 (en) | 1999-06-22 | 2004-02-24 | Board Of Regents, The University Of Texas System | Apparatus for the characterization of tissue of epithelial lined viscus |
| US6445939B1 (en) | 1999-08-09 | 2002-09-03 | Lightlab Imaging, Llc | Ultra-small optical probes, imaging optics, and methods for using same |
| DE60045146D1 (en) * | 1999-11-02 | 2010-12-09 | Fujifilm Corp | Device for displaying fluorescence |
| US6845326B1 (en) | 1999-11-08 | 2005-01-18 | Ndsu Research Foundation | Optical sensor for analyzing a stream of an agricultural product to determine its constituents |
| US6624888B2 (en) * | 2000-01-12 | 2003-09-23 | North Dakota State University | On-the-go sugar sensor for determining sugar content during harvesting |
| EP1259163A4 (en) | 2000-02-08 | 2006-05-03 | Cornell Res Foundation Inc | Multiphoton excitation through optical fibers for fluorescence spectroscopy |
| CA2400305A1 (en) * | 2000-02-18 | 2001-08-23 | Argose,Inc. | Generation of spatially-averaged excitation-emission map in heterogeneous tissue |
| AU2001251114A1 (en) | 2000-03-28 | 2001-10-08 | Board Of Regents, The University Of Texas System | Enhancing contrast in biological imaging |
| GR1004180B (en) | 2000-03-28 | 2003-03-11 | ����������� ����� ��������� (����) | Method and system for characterization and mapping of tissue lesions |
| US6377841B1 (en) * | 2000-03-31 | 2002-04-23 | Vanderbilt University | Tumor demarcation using optical spectroscopy |
| AU5113401A (en) * | 2000-03-31 | 2001-10-15 | Rita Medical Systems Inc | Tissue biopsy and treatment apparatus and method |
| US20040044287A1 (en) * | 2000-03-31 | 2004-03-04 | Wei-Chiang Lin | Identification of human tissue using optical spectroscopy |
| US6748259B1 (en) * | 2000-06-15 | 2004-06-08 | Spectros Corporation | Optical imaging of induced signals in vivo under ambient light conditions |
| US6821245B2 (en) | 2000-07-14 | 2004-11-23 | Xillix Technologies Corporation | Compact fluorescence endoscopy video system |
| US20020107448A1 (en) * | 2000-10-06 | 2002-08-08 | Gandjbakhche Amir H. | Probe using diffuse-reflectance spectroscopy |
| JP4241038B2 (en) | 2000-10-30 | 2009-03-18 | ザ ジェネラル ホスピタル コーポレーション | Optical method and system for tissue analysis |
| WO2002064084A2 (en) * | 2000-11-02 | 2002-08-22 | Cornell Research Foundation, Inc. | In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease |
| US9295391B1 (en) | 2000-11-10 | 2016-03-29 | The General Hospital Corporation | Spectrally encoded miniature endoscopic imaging probe |
| US6566656B2 (en) * | 2000-11-30 | 2003-05-20 | Electronic Instrumentation & Technology, Inc. | Probe style radiometer |
| US6839661B2 (en) * | 2000-12-15 | 2005-01-04 | Medispectra, Inc. | System for normalizing spectra |
| US6697652B2 (en) | 2001-01-19 | 2004-02-24 | Massachusetts Institute Of Technology | Fluorescence, reflectance and light scattering spectroscopy for measuring tissue |
| DE10108712A1 (en) * | 2001-02-23 | 2002-09-12 | Warsteiner Brauerei Haus Crame | Method for analytical analysis of a beer sample |
| US20040038320A1 (en) * | 2001-03-09 | 2004-02-26 | Bhaskar Banerjee | Methods of detecting cancer using cellular autofluorescence |
| GB0106342D0 (en) * | 2001-03-15 | 2001-05-02 | Renishaw Plc | Spectroscopy apparatus and method |
| US8581697B2 (en) * | 2001-04-11 | 2013-11-12 | Trutouch Technologies Inc. | Apparatuses for noninvasive determination of in vivo alcohol concentration using raman spectroscopy |
| US20130317328A1 (en) * | 2001-04-11 | 2013-11-28 | Tru Touch Technologies, Inc. | Methods and Apparatuses for Noninvasive Determination of in vivo Alcohol Concentration using Raman Spectroscopy |
| EP2333523B1 (en) | 2001-04-30 | 2020-04-08 | The General Hospital Corporation | Method and apparatus for improving image clarity and sensitivity in optical coherence tomography using dynamic feedback to control focal properties and coherence gating |
| US7865231B2 (en) | 2001-05-01 | 2011-01-04 | The General Hospital Corporation | Method and apparatus for determination of atherosclerotic plaque type by measurement of tissue optical properties |
| US6796710B2 (en) * | 2001-06-08 | 2004-09-28 | Ethicon Endo-Surgery, Inc. | System and method of measuring and controlling temperature of optical fiber tip in a laser system |
| DE60237501D1 (en) * | 2001-06-20 | 2010-10-14 | Dainippon Printing Co Ltd | BATTERY PACKAGING MATERIAL |
| US20030045798A1 (en) * | 2001-09-04 | 2003-03-06 | Richard Hular | Multisensor probe for tissue identification |
| US6980299B1 (en) | 2001-10-16 | 2005-12-27 | General Hospital Corporation | Systems and methods for imaging a sample |
| US20040238732A1 (en) * | 2001-10-19 | 2004-12-02 | Andrei State | Methods and systems for dynamic virtual convergence and head mountable display |
| US7116414B2 (en) * | 2001-11-09 | 2006-10-03 | Exxonmobil Chemical Patents Inc. | On-line measurement and control of polymer properties by raman spectroscopy |
| WO2003043492A1 (en) | 2001-11-20 | 2003-05-30 | University Health Network | Optical transillumination and reflectance spectroscopy to quantify disease risk |
| US7039452B2 (en) | 2002-12-19 | 2006-05-02 | The University Of Utah Research Foundation | Method and apparatus for Raman imaging of macular pigments |
| WO2003060423A2 (en) | 2002-01-11 | 2003-07-24 | The General Hospital Corporation | Apparatus for low coherence ranging |
| US20060241496A1 (en) * | 2002-01-15 | 2006-10-26 | Xillix Technologies Corp. | Filter for use with imaging endoscopes |
| US7355716B2 (en) | 2002-01-24 | 2008-04-08 | The General Hospital Corporation | Apparatus and method for ranging and noise reduction of low coherence interferometry LCI and optical coherence tomography OCT signals by parallel detection of spectral bands |
| US20040023415A1 (en) * | 2002-03-05 | 2004-02-05 | Konstantin Sokolov | Biospecific contrast agents |
| US7647092B2 (en) * | 2002-04-05 | 2010-01-12 | Massachusetts Institute Of Technology | Systems and methods for spectroscopy of biological tissue |
| US20040073120A1 (en) * | 2002-04-05 | 2004-04-15 | Massachusetts Institute Of Technology | Systems and methods for spectroscopy of biological tissue |
| US7257437B2 (en) * | 2002-07-05 | 2007-08-14 | The Regents Of The University Of California | Autofluorescence detection and imaging of bladder cancer realized through a cystoscope |
| US6818903B2 (en) | 2002-07-09 | 2004-11-16 | Medispectra, Inc. | Method and apparatus for identifying spectral artifacts |
| US6768918B2 (en) | 2002-07-10 | 2004-07-27 | Medispectra, Inc. | Fluorescent fiberoptic probe for tissue health discrimination and method of use thereof |
| US7103401B2 (en) * | 2002-07-10 | 2006-09-05 | Medispectra, Inc. | Colonic polyp discrimination by tissue fluorescence and fiberoptic probe |
| US20040068193A1 (en) * | 2002-08-02 | 2004-04-08 | Barnes Russell H. | Optical devices for medical diagnostics |
| US7376456B2 (en) * | 2002-08-05 | 2008-05-20 | Infraredx, Inc. | Near-infrared spectroscopic analysis of blood vessel walls |
| US7689268B2 (en) * | 2002-08-05 | 2010-03-30 | Infraredx, Inc. | Spectroscopic unwanted signal filters for discrimination of vulnerable plaque and method therefor |
| IL151745A (en) | 2002-09-12 | 2007-10-31 | Uzi Sharon | Explosive detection and identification system |
| US20040064053A1 (en) * | 2002-09-30 | 2004-04-01 | Chang Sung K. | Diagnostic fluorescence and reflectance |
| CA2501528A1 (en) * | 2002-10-15 | 2004-04-15 | Exxonmobil Chemical Patents Inc. | On-line measurement and control of polymer properties by raman spectroscopy |
| US6980573B2 (en) * | 2002-12-09 | 2005-12-27 | Infraredx, Inc. | Tunable spectroscopic source with power stability and method of operation |
| US8054468B2 (en) | 2003-01-24 | 2011-11-08 | The General Hospital Corporation | Apparatus and method for ranging and noise reduction of low coherence interferometry LCI and optical coherence tomography OCT signals by parallel detection of spectral bands |
| WO2004088361A2 (en) | 2003-03-31 | 2004-10-14 | The General Hospital Corporation | Speckle reduction in optical coherence tomography by path length encoded angular compounding |
| EP2319405B1 (en) | 2003-01-24 | 2013-09-18 | The General Hospital Corporation | System and method for identifying tissue using low-coherence interferometry |
| US20040254479A1 (en) | 2003-02-20 | 2004-12-16 | John Fralick | Bio-photonic feedback control software and database |
| US7326576B2 (en) * | 2003-04-09 | 2008-02-05 | Prescient Medical, Inc. | Raman spectroscopic monitoring of hemodialysis |
| US6914668B2 (en) * | 2003-05-14 | 2005-07-05 | International Technologies (Laser) Ltd. | Personal identification verification and controlled substance detection and identification system |
| US7181219B2 (en) | 2003-05-22 | 2007-02-20 | Lucent Technologies Inc. | Wireless handover using anchor termination |
| KR101386971B1 (en) | 2003-06-06 | 2014-04-18 | 더 제너럴 하스피탈 코포레이션 | Process and apparatus for a wavelength tunning source |
| JP2005024456A (en) * | 2003-07-04 | 2005-01-27 | Mitsubishi Chemicals Corp | Surface plasmon resonance sensor, and biosensor |
| WO2005057244A2 (en) * | 2003-08-19 | 2005-06-23 | Cornell Research Foundation, Inc. | Optical fiber delivery and collection system for biological applications |
| US7733497B2 (en) | 2003-10-27 | 2010-06-08 | The General Hospital Corporation | Method and apparatus for performing optical imaging using frequency-domain interferometry |
| EP1687587B1 (en) | 2003-11-28 | 2020-01-08 | The General Hospital Corporation | Method and apparatus for three-dimensional spectrally encoded imaging |
| US8326404B2 (en) * | 2003-11-28 | 2012-12-04 | British Columbia Cancer Agency Branch | Multimodal detection of tissue abnormalities based on raman and background fluorescence spectroscopy |
| US20050278184A1 (en) | 2004-06-10 | 2005-12-15 | John Fralick | Bio-photonic feedback control software and database |
| US8868147B2 (en) | 2004-04-28 | 2014-10-21 | Glt Acquisition Corp. | Method and apparatus for controlling positioning of a noninvasive analyzer sample probe |
| US20050250091A1 (en) * | 2004-05-05 | 2005-11-10 | Chemlmage Corporation | Raman molecular imaging for detection of bladder cancer |
| US7697576B2 (en) | 2004-05-05 | 2010-04-13 | Chem Image Corporation | Cytological analysis by raman spectroscopic imaging |
| US8730047B2 (en) | 2004-05-24 | 2014-05-20 | Trutouch Technologies, Inc. | System for noninvasive determination of analytes in tissue |
| US8515506B2 (en) | 2004-05-24 | 2013-08-20 | Trutouch Technologies, Inc. | Methods for noninvasive determination of in vivo alcohol concentration using Raman spectroscopy |
| AU2004320269B2 (en) | 2004-05-29 | 2011-07-21 | The General Hospital Corporation | Process, system and software arrangement for a chromatic dispersion compensation using reflective layers in optical coherence tomography (OCT) imaging |
| US7136158B2 (en) * | 2004-06-10 | 2006-11-14 | Uchicago Argonne Llc | Optical apparatus for laser scattering by objects having complex shapes |
| WO2006014392A1 (en) | 2004-07-02 | 2006-02-09 | The General Hospital Corporation | Endoscopic imaging probe comprising dual clad fibre |
| US8081316B2 (en) | 2004-08-06 | 2011-12-20 | The General Hospital Corporation | Process, system and software arrangement for determining at least one location in a sample using an optical coherence tomography |
| US8208995B2 (en) | 2004-08-24 | 2012-06-26 | The General Hospital Corporation | Method and apparatus for imaging of vessel segments |
| WO2006024014A2 (en) | 2004-08-24 | 2006-03-02 | The General Hospital Corporation | Process, system and software arrangement for measuring a mechanical strain and elastic properties of a sample |
| US7365859B2 (en) | 2004-09-10 | 2008-04-29 | The General Hospital Corporation | System and method for optical coherence imaging |
| EP2329759B1 (en) | 2004-09-29 | 2014-03-12 | The General Hospital Corporation | System and method for optical coherence imaging |
| KR100700913B1 (en) * | 2004-10-20 | 2007-03-28 | 고려대학교 산학협력단 | Method for reducing auto-fluorescence signals in confocal Raman microscopy |
| JP5623692B2 (en) | 2004-11-02 | 2014-11-12 | ザ ジェネラル ホスピタル コーポレイション | Optical fiber rotator, optical system and method for sample imaging |
| US7365839B2 (en) * | 2004-11-03 | 2008-04-29 | Nu Skin International, Inc. | Process and compositions for synthetic calibration of bio-photonic scanners |
| US7995210B2 (en) | 2004-11-24 | 2011-08-09 | The General Hospital Corporation | Devices and arrangements for performing coherence range imaging using a common path interferometer |
| JP2008521516A (en) | 2004-11-29 | 2008-06-26 | ザ ジェネラル ホスピタル コーポレイション | Configuration, apparatus, endoscope, catheter, and method for performing optical image generation by simultaneously illuminating and detecting multiple points on a sample |
| WO2006062987A2 (en) * | 2004-12-09 | 2006-06-15 | Inneroptic Technology, Inc. | Apparatus, system and method for optically analyzing substrate |
| US20060244913A1 (en) | 2004-12-21 | 2006-11-02 | Werner Gellermann | Imaging of macular pigment distributions |
| US20060134004A1 (en) * | 2004-12-21 | 2006-06-22 | The University Of Utah | Methods and apparatus for detection of carotenoids in macular tissue |
| US7307774B1 (en) | 2005-01-24 | 2007-12-11 | The Board Of Trustees Of The Leland Standford Junior University | Micro-optical analysis system and approach therefor |
| US8788021B1 (en) | 2005-01-24 | 2014-07-22 | The Board Of Trustees Of The Leland Stanford Junior Univerity | Live being optical analysis system and approach |
| US8346346B1 (en) | 2005-01-24 | 2013-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Optical analysis system and approach therefor |
| US7651851B2 (en) | 2005-01-27 | 2010-01-26 | Prescient Medical, Inc. | Handheld Raman body fluid analyzer |
| US7524671B2 (en) | 2005-01-27 | 2009-04-28 | Prescient Medical, Inc. | Handheld raman blood analyzer |
| US7688440B2 (en) | 2005-01-27 | 2010-03-30 | Prescient Medical, Inc. | Raman spectroscopic test strip systems |
| TW200631543A (en) * | 2005-03-11 | 2006-09-16 | Everest Display Inc | Embedded multiband detecting device in vivo |
| EP2325803A1 (en) | 2005-04-28 | 2011-05-25 | The General Hospital Corporation | Evaluating optical coherence tomography information for an anatomical structure |
| DE102005022880B4 (en) * | 2005-05-18 | 2010-12-30 | Olympus Soft Imaging Solutions Gmbh | Separation of spectrally or color superimposed image contributions in a multi-color image, especially in transmission microscopic multi-color images |
| EP1887926B1 (en) | 2005-05-31 | 2014-07-30 | The General Hospital Corporation | System and method which use spectral encoding heterodyne interferometry techniques for imaging |
| US9060689B2 (en) | 2005-06-01 | 2015-06-23 | The General Hospital Corporation | Apparatus, method and system for performing phase-resolved optical frequency domain imaging |
| WO2007002323A2 (en) * | 2005-06-23 | 2007-01-04 | Epoc, Inc. | System and method for monitoring of end organ oxygenation by measurement of in vivo cellular energy status |
| WO2007006039A2 (en) * | 2005-07-05 | 2007-01-11 | The Board Of Regents Of The University Of Texas System | Depth-resolved spectroscopy method and apparatus |
| US20070167835A1 (en) * | 2005-07-25 | 2007-07-19 | Massachusetts Institute Of Technology | Tri modal spectroscopic imaging |
| US20070167836A1 (en) * | 2005-07-25 | 2007-07-19 | Massachusetts Institute Of Technology | Multi modal spectroscopy |
| ES2354287T3 (en) | 2005-08-09 | 2011-03-11 | The General Hospital Corporation | APPARATUS AND METHOD FOR PERFORMING A DEMODULATION IN QUADRATURE BY POLARIZATION IN OPTICAL COHERENCE TOMOGRAPHY. |
| WO2007038679A2 (en) * | 2005-09-27 | 2007-04-05 | Chemimage Corporation | Method for correlating spectroscopic measurements with digital images of contrast enhanced tissue |
| CN101365375B (en) | 2005-09-29 | 2013-09-11 | 通用医疗公司 | Method and apparatus for optical imaging via spectral encoding |
| US20070270717A1 (en) * | 2005-09-30 | 2007-11-22 | Cornova, Inc. | Multi-faceted optical reflector |
| EP1942793A2 (en) | 2005-09-30 | 2008-07-16 | Cornova, Inc. | Systems and methods for analysis and treatment of a body lumen |
| US20100286531A1 (en) * | 2005-09-30 | 2010-11-11 | Cornova, Inc. | Systems and methods for analysis and treatment of a body lumen |
| US7558619B2 (en) * | 2005-10-04 | 2009-07-07 | Nu Skin International, Inc. | Raman instrument for measuring weak signals in the presence of strong background fluorescence |
| US20070173736A1 (en) * | 2005-10-07 | 2007-07-26 | Femspec Llc | Apparatus and methods for endometrial biopsies |
| US7889348B2 (en) | 2005-10-14 | 2011-02-15 | The General Hospital Corporation | Arrangements and methods for facilitating photoluminescence imaging |
| US7519253B2 (en) | 2005-11-18 | 2009-04-14 | Omni Sciences, Inc. | Broadband or mid-infrared fiber light sources |
| EP1971848B1 (en) | 2006-01-10 | 2019-12-04 | The General Hospital Corporation | Systems and methods for generating data based on one or more spectrally-encoded endoscopy techniques |
| US8145018B2 (en) | 2006-01-19 | 2012-03-27 | The General Hospital Corporation | Apparatus for obtaining information for a structure using spectrally-encoded endoscopy techniques and methods for producing one or more optical arrangements |
| PL1973466T3 (en) | 2006-01-19 | 2021-07-05 | The General Hospital Corporation | Ballon imaging catheter |
| JP5524487B2 (en) | 2006-02-01 | 2014-06-18 | ザ ジェネラル ホスピタル コーポレイション | A method and system for emitting electromagnetic radiation to at least a portion of a sample using a conformal laser treatment procedure. |
| WO2007149603A2 (en) | 2006-02-01 | 2007-12-27 | The General Hospital Corporation | Apparatus for applying a plurality of electro-magnetic radiations to a sample |
| WO2007149601A2 (en) | 2006-02-01 | 2007-12-27 | The General Hospital Corporation | Apparatus for controlling at least one of at least two sections of at least one fiber |
| WO2007092173A2 (en) * | 2006-02-06 | 2007-08-16 | Prescient Medical, Inc. | Raman spectroscopic lateral flow test strip assays |
| US20090303317A1 (en) | 2006-02-07 | 2009-12-10 | Novadaq Technologies Inc. | Near infrared imaging |
| JP5519152B2 (en) | 2006-02-08 | 2014-06-11 | ザ ジェネラル ホスピタル コーポレイション | Device for acquiring information about anatomical samples using optical microscopy |
| EP1987318B1 (en) | 2006-02-24 | 2015-08-12 | The General Hospital Corporation | Methods and systems for performing angle-resolved fourier-domain optical coherence tomography |
| JP5135324B2 (en) | 2006-04-05 | 2013-02-06 | ザ ジェネラル ホスピタル コーポレイション | Method, arrangement and system for polarization sensitive optical frequency domain imaging of samples |
| FR2900043B1 (en) * | 2006-04-24 | 2008-07-04 | Commissariat Energie Atomique | METHOD FOR OPTICALLY IMAGING FLUORESCENCE OF BIOLOGICAL TISSUES, IN PARTICULAR TO DELIMIT REGIONS OF INTEREST FROM TISSUES TO BE ANALYZED BY TOMOGRAPHY |
| EP2517616A3 (en) | 2006-05-10 | 2013-03-06 | The General Hospital Corporation | Processes, arrangements and systems for providing frequency domain imaging of a sample |
| WO2007133964A2 (en) * | 2006-05-12 | 2007-11-22 | The General Hospital Corporation | Processes, arrangements and systems for providing a fiber layer thickness map based on optical coherence tomography images |
| US20110057930A1 (en) * | 2006-07-26 | 2011-03-10 | Inneroptic Technology Inc. | System and method of using high-speed, high-resolution depth extraction to provide three-dimensional imagery for endoscopy |
| WO2008011722A1 (en) | 2006-07-28 | 2008-01-31 | Novadaq Technologies Inc. | System and method for deposition and removal of an optical element on an endoscope objective |
| US7728868B2 (en) | 2006-08-02 | 2010-06-01 | Inneroptic Technology, Inc. | System and method of providing real-time dynamic imagery of a medical procedure site using multiple modalities |
| CN101589301B (en) | 2006-08-25 | 2012-11-07 | 通用医疗公司 | Apparatus and methods for enhancing optical coherence tomography imaging using volumetric filtering techniques |
| WO2009089372A2 (en) * | 2008-01-08 | 2009-07-16 | Cornova, Inc. | Systems and methods for analysis and treatment of a body lumen |
| WO2008049118A2 (en) | 2006-10-19 | 2008-04-24 | The General Hospital Corporation | Apparatus and method for obtaining and providing imaging information associated with at least one portion of a sample and effecting such portion(s) |
| US8155730B2 (en) * | 2006-10-24 | 2012-04-10 | The Research Foundation Of State University Of New York | Composition, method, system, and kit for optical electrophysiology |
| US7654716B1 (en) | 2006-11-10 | 2010-02-02 | Doheny Eye Institute | Enhanced visualization illumination system |
| WO2008066911A2 (en) * | 2006-11-30 | 2008-06-05 | Newton Laboratories, Inc. | Spectroscopically enhanced imaging |
| US8498695B2 (en) | 2006-12-22 | 2013-07-30 | Novadaq Technologies Inc. | Imaging system with a single color image sensor for simultaneous fluorescence and color video endoscopy |
| US8787633B2 (en) * | 2007-01-16 | 2014-07-22 | Purdue Research Foundation | System and method of organism identification |
| US7949019B2 (en) | 2007-01-19 | 2011-05-24 | The General Hospital | Wavelength tuning source based on a rotatable reflector |
| US7911621B2 (en) | 2007-01-19 | 2011-03-22 | The General Hospital Corporation | Apparatus and method for controlling ranging depth in optical frequency domain imaging |
| WO2008106590A2 (en) | 2007-02-28 | 2008-09-04 | Doheny Eye Institute | Portable handheld illumination system |
| EP2602651A3 (en) | 2007-03-23 | 2014-08-27 | The General Hospital Corporation | Methods, arrangements and apparatus for utilizing a wavelength-swept laser using angular scanning and dispersion procedures |
| US10534129B2 (en) | 2007-03-30 | 2020-01-14 | The General Hospital Corporation | System and method providing intracoronary laser speckle imaging for the detection of vulnerable plaque |
| WO2008131082A1 (en) | 2007-04-17 | 2008-10-30 | The General Hospital Corporation | Apparatus and methods for measuring vibrations using spectrally-encoded endoscopy techniques |
| US8115919B2 (en) | 2007-05-04 | 2012-02-14 | The General Hospital Corporation | Methods, arrangements and systems for obtaining information associated with a sample using optical microscopy |
| US20100174196A1 (en) * | 2007-06-21 | 2010-07-08 | Cornova, Inc. | Systems and methods for guiding the analysis and treatment of a body lumen |
| JP5917803B2 (en) | 2007-07-31 | 2016-05-18 | ザ ジェネラル ホスピタル コーポレイション | System and method for emitting a beam scanning pattern for fast Doppler optical frequency domain imaging |
| US20090062662A1 (en) * | 2007-08-27 | 2009-03-05 | Remicalm, Llc | Optical spectroscopic device for the identification of cervical cancer |
| EP2191254B1 (en) | 2007-08-31 | 2017-07-19 | The General Hospital Corporation | System and method for self-interference fluorescence microscopy, and computer-accessible medium associated therewith |
| US20090099460A1 (en) * | 2007-10-16 | 2009-04-16 | Remicalm Llc | Method and device for the optical spectroscopic identification of cervical cancer |
| WO2009059034A1 (en) | 2007-10-30 | 2009-05-07 | The General Hospital Corporation | System and method for cladding mode detection |
| WO2009094646A2 (en) * | 2008-01-24 | 2009-07-30 | The University Of North Carolina At Chapel Hill | Methods, systems, and computer readable media for image guided ablation |
| US11123047B2 (en) | 2008-01-28 | 2021-09-21 | The General Hospital Corporation | Hybrid systems and methods for multi-modal acquisition of intravascular imaging data and counteracting the effects of signal absorption in blood |
| US9332942B2 (en) | 2008-01-28 | 2016-05-10 | The General Hospital Corporation | Systems, processes and computer-accessible medium for providing hybrid flourescence and optical coherence tomography imaging |
| US7979363B1 (en) * | 2008-03-06 | 2011-07-12 | Thomas Cecil Minter | Priori probability and probability of error estimation for adaptive bayes pattern recognition |
| US8340379B2 (en) | 2008-03-07 | 2012-12-25 | Inneroptic Technology, Inc. | Systems and methods for displaying guidance data based on updated deformable imaging data |
| JP5231625B2 (en) | 2008-03-18 | 2013-07-10 | ノヴァダク テクノロジーズ インコーポレイテッド | Imaging system for acquiring NIR and full color images and method of operation thereof |
| EP2274572A4 (en) | 2008-05-07 | 2013-08-28 | Gen Hospital Corp | System, method and computer-accessible medium for tracking vessel motion during three-dimensional coronary artery microscopy |
| CA2891990C (en) | 2008-05-20 | 2022-07-26 | Ralph Sebastian Dacosta | Device and method for fluorescence-based imaging and monitoring |
| WO2009155536A2 (en) | 2008-06-20 | 2009-12-23 | The General Hospital Corporation | Fused fiber optic coupler arrangement and method for use thereof |
| WO2010009136A2 (en) | 2008-07-14 | 2010-01-21 | The General Hospital Corporation | Apparatus and methods for color endoscopy |
| WO2010022330A2 (en) * | 2008-08-21 | 2010-02-25 | University Of Florida Research Foundation, Inc. | Differential laser-induced perturbation (dlip) for bioimaging and chemical sensing |
| US20100249607A1 (en) * | 2008-09-26 | 2010-09-30 | Massachusetts Institute Of Technology | Quantitative spectroscopic imaging |
| WO2010056347A1 (en) * | 2008-11-14 | 2010-05-20 | Sti Medical Systems, Llc | Process and device for detection of precancer tissues with infrared spectroscopy. |
| JP5731394B2 (en) | 2008-12-10 | 2015-06-10 | ザ ジェネラル ホスピタル コーポレイション | System, apparatus and method for extending imaging depth range of optical coherence tomography through optical subsampling |
| GB2466442A (en) | 2008-12-18 | 2010-06-23 | Dublin Inst Of Technology | A system to analyze a sample on a slide using Raman spectroscopy on an identified area of interest |
| US9814417B2 (en) * | 2009-01-13 | 2017-11-14 | Longevity Link Corporation | Noninvasive measurement of flavonoid compounds in biological tissue |
| WO2010085775A2 (en) | 2009-01-26 | 2010-07-29 | The General Hospital Corporation | System, method and computer-accessible medium for providing wide-field superresolution microscopy |
| CN102308444B (en) | 2009-02-04 | 2014-06-18 | 通用医疗公司 | Apparatus and method for utilization of a high-speed optical wavelength tuning source |
| US8641621B2 (en) | 2009-02-17 | 2014-02-04 | Inneroptic Technology, Inc. | Systems, methods, apparatuses, and computer-readable media for image management in image-guided medical procedures |
| US8554307B2 (en) | 2010-04-12 | 2013-10-08 | Inneroptic Technology, Inc. | Image annotation in image-guided medical procedures |
| US11464578B2 (en) | 2009-02-17 | 2022-10-11 | Inneroptic Technology, Inc. | Systems, methods, apparatuses, and computer-readable media for image management in image-guided medical procedures |
| US8690776B2 (en) | 2009-02-17 | 2014-04-08 | Inneroptic Technology, Inc. | Systems, methods, apparatuses, and computer-readable media for image guided surgery |
| US9351642B2 (en) | 2009-03-12 | 2016-05-31 | The General Hospital Corporation | Non-contact optical system, computer-accessible medium and method for measurement at least one mechanical property of tissue using coherent speckle technique(s) |
| BR112012001042A2 (en) | 2009-07-14 | 2016-11-22 | Gen Hospital Corp | fluid flow measurement equipment and method within anatomical structure. |
| WO2011014687A2 (en) * | 2009-07-31 | 2011-02-03 | Inneroptic Technology, Inc. | Dual-tube stereoscope |
| US20110082351A1 (en) * | 2009-10-07 | 2011-04-07 | Inneroptic Technology, Inc. | Representing measurement information during a medical procedure |
| US9282947B2 (en) | 2009-12-01 | 2016-03-15 | Inneroptic Technology, Inc. | Imager focusing based on intraoperative data |
| AU2010333666A1 (en) * | 2009-12-17 | 2012-07-12 | British Columbia Cancer Agency Branch | Apparatus and methods for in vivo tissue characterization by Raman spectroscopy |
| CA2786262A1 (en) | 2010-01-07 | 2011-07-14 | Cheetah Omni, Llc | Fiber lasers and mid-infrared light sources in methods and systems for selective biological tissue processing and spectroscopy |
| ES2831223T3 (en) | 2010-03-05 | 2021-06-07 | Massachusetts Gen Hospital | Apparatus for providing electromagnetic radiation to a sample |
| US9069130B2 (en) | 2010-05-03 | 2015-06-30 | The General Hospital Corporation | Apparatus, method and system for generating optical radiation from biological gain media |
| EP3372206A1 (en) | 2010-05-13 | 2018-09-12 | Doheny Eye Institute | Self contained illuminated infusion cannula systems and devices |
| US9795301B2 (en) | 2010-05-25 | 2017-10-24 | The General Hospital Corporation | Apparatus, systems, methods and computer-accessible medium for spectral analysis of optical coherence tomography images |
| US9557154B2 (en) | 2010-05-25 | 2017-01-31 | The General Hospital Corporation | Systems, devices, methods, apparatus and computer-accessible media for providing optical imaging of structures and compositions |
| US9606057B2 (en) | 2010-06-01 | 2017-03-28 | Todos Medical Ltd. | Biochemical analysis of PBMC |
| EP2575591A4 (en) | 2010-06-03 | 2017-09-13 | The General Hospital Corporation | Apparatus and method for devices for imaging structures in or at one or more luminal organs |
| JP5800595B2 (en) * | 2010-08-27 | 2015-10-28 | キヤノン株式会社 | Medical diagnosis support apparatus, medical diagnosis support system, medical diagnosis support control method, and program |
| US20120052063A1 (en) * | 2010-08-31 | 2012-03-01 | The Board Of Trustees Of The University Of Illinois | Automated detection of breast cancer lesions in tissue |
| US9510758B2 (en) | 2010-10-27 | 2016-12-06 | The General Hospital Corporation | Apparatus, systems and methods for measuring blood pressure within at least one vessel |
| CN103765091B (en) | 2011-03-08 | 2017-09-26 | 诺瓦达克技术公司 | Full spectrum LED illuminator |
| US20120252058A1 (en) * | 2011-03-29 | 2012-10-04 | Chemimage Corporation | System and Method for the Assessment of Biological Particles in Exhaled Air |
| WO2012149175A1 (en) | 2011-04-29 | 2012-11-01 | The General Hospital Corporation | Means for determining depth-resolved physical and/or optical properties of scattering media |
| WO2012153326A1 (en) | 2011-05-11 | 2012-11-15 | Todos Medical Ltd. | Diagnosis of cancer |
| US8760645B2 (en) | 2011-05-24 | 2014-06-24 | Idexx Laboratories Inc. | Method of normalizing a fluorescence analyzer |
| US20120314200A1 (en) * | 2011-06-09 | 2012-12-13 | Ophir Eyal | Coupled multi-wavelength confocal systems for distance measurements |
| WO2013013049A1 (en) | 2011-07-19 | 2013-01-24 | The General Hospital Corporation | Systems, methods, apparatus and computer-accessible-medium for providing polarization-mode dispersion compensation in optical coherence tomography |
| US10241028B2 (en) | 2011-08-25 | 2019-03-26 | The General Hospital Corporation | Methods, systems, arrangements and computer-accessible medium for providing micro-optical coherence tomography procedures |
| EP2769491A4 (en) | 2011-10-18 | 2015-07-22 | Gen Hospital Corp | Apparatus and methods for producing and/or providing recirculating optical delay(s) |
| US20150011893A1 (en) * | 2011-11-09 | 2015-01-08 | The University Of British Columbia | Evaluation of skin lesions by raman spectroscopy |
| US20130135608A1 (en) * | 2011-11-30 | 2013-05-30 | Reflectronics, Inc. | Apparatus and method for improved processing of food products |
| US20130231949A1 (en) * | 2011-12-16 | 2013-09-05 | Dimitar V. Baronov | Systems and methods for transitioning patient care from signal-based monitoring to risk-based monitoring |
| US11676730B2 (en) | 2011-12-16 | 2023-06-13 | Etiometry Inc. | System and methods for transitioning patient care from signal based monitoring to risk based monitoring |
| EA033790B1 (en) * | 2011-12-19 | 2019-11-26 | Opticul Diagnostics Ltd | Method for spectroscopic detecting and identifying microorganisms in culture |
| WO2013116240A1 (en) | 2012-01-30 | 2013-08-08 | Inneroptic Technology, Inc. | Multiple medical device guidance |
| WO2013148306A1 (en) | 2012-03-30 | 2013-10-03 | The General Hospital Corporation | Imaging system, method and distal attachment for multidirectional field of view endoscopy |
| JP6398093B2 (en) * | 2012-04-13 | 2018-10-03 | ベイカー ハート アンド ダイアベーツ インスティテュート | Detection of atherosclerotic plaque |
| WO2013177154A1 (en) | 2012-05-21 | 2013-11-28 | The General Hospital Corporation | Apparatus, device and method for capsule microscopy |
| JP6227652B2 (en) | 2012-08-22 | 2017-11-08 | ザ ジェネラル ホスピタル コーポレイション | System, method, and computer-accessible medium for fabricating a miniature endoscope using soft lithography |
| DE102012217676B4 (en) * | 2012-09-27 | 2016-05-04 | Secopta Gmbh | Method for identifying the composition of a sample |
| WO2014120791A1 (en) | 2013-01-29 | 2014-08-07 | The General Hospital Corporation | Apparatus, systems and methods for providing information regarding the aortic valve |
| US11179028B2 (en) | 2013-02-01 | 2021-11-23 | The General Hospital Corporation | Objective lens arrangement for confocal endomicroscopy |
| US10314559B2 (en) | 2013-03-14 | 2019-06-11 | Inneroptic Technology, Inc. | Medical device guidance |
| WO2014168734A1 (en) | 2013-03-15 | 2014-10-16 | Cedars-Sinai Medical Center | Time-resolved laser-induced fluorescence spectroscopy systems and uses thereof |
| JP6378311B2 (en) | 2013-03-15 | 2018-08-22 | ザ ジェネラル ホスピタル コーポレイション | Methods and systems for characterizing objects |
| WO2014186353A1 (en) | 2013-05-13 | 2014-11-20 | The General Hospital Corporation | Detecting self-interefering fluorescence phase and amplitude |
| JP2014221117A (en) * | 2013-05-13 | 2014-11-27 | 株式会社アライ・メッドフォトン研究所 | Therapy progress degree monitoring device and method for therapy progress degree monitoring |
| US9804145B2 (en) | 2013-05-28 | 2017-10-31 | Todos Medical Ltd. | Infrared analysis of benign tumors |
| EP3003177B1 (en) | 2013-05-31 | 2021-03-10 | Covidien LP | Surgical device with an end-effector assembly for monitoring of tissue during a surgical procedure |
| EP3021735A4 (en) | 2013-07-19 | 2017-04-19 | The General Hospital Corporation | Determining eye motion by imaging retina. with feedback |
| WO2015009932A1 (en) | 2013-07-19 | 2015-01-22 | The General Hospital Corporation | Imaging apparatus and method which utilizes multidirectional field of view endoscopy |
| EP3025173B1 (en) | 2013-07-26 | 2021-07-07 | The General Hospital Corporation | Apparatus with a laser arrangement utilizing optical dispersion for applications in fourier-domain optical coherence tomography |
| WO2015116298A2 (en) * | 2013-11-12 | 2015-08-06 | California Institute Of Technology | Method and system for raman spectroscopy using plasmon heating |
| US20150149940A1 (en) * | 2013-11-27 | 2015-05-28 | General Electric Company | Medical Test Result Presentation |
| US9733460B2 (en) | 2014-01-08 | 2017-08-15 | The General Hospital Corporation | Method and apparatus for microscopic imaging |
| WO2015116986A2 (en) | 2014-01-31 | 2015-08-06 | The General Hospital Corporation | System and method for facilitating manual and/or automatic volumetric imaging with real-time tension or force feedback using a tethered imaging device |
| WO2015153982A1 (en) | 2014-04-04 | 2015-10-08 | The General Hospital Corporation | Apparatus and method for controlling propagation and/or transmission of electromagnetic radiation in flexible waveguide(s) |
| CN103989459B (en) * | 2014-05-20 | 2021-05-18 | 曾堃 | Optical observation device and endoscope for identifying malignant tumor formation process |
| DE102014107342B4 (en) | 2014-05-24 | 2023-05-04 | Frank Braun | Device and method for detecting cancerous tumors and other tissue changes |
| JP5864674B2 (en) * | 2014-05-29 | 2016-02-17 | シャープ株式会社 | Measuring probe, measuring device and attachment mechanism |
| US20150346102A1 (en) * | 2014-06-03 | 2015-12-03 | Innovative Photonic Solutions, Inc. | Compact Raman Probe Integrated with Wavelength Stabilized Diode Laser Source |
| DK3171765T3 (en) | 2014-07-24 | 2021-11-01 | Univ Health Network | COLLECTION AND ANALYSIS OF DATA FOR DIAGNOSTIC PURPOSES |
| WO2016015052A1 (en) * | 2014-07-25 | 2016-01-28 | The General Hospital Corporation | Apparatus, devices and methods for in vivo imaging and diagnosis |
| KR101626045B1 (en) * | 2014-07-29 | 2016-06-01 | 경희대학교 산학협력단 | A method and device for diagnosis of viral infection using tear drop |
| JP2017534321A (en) * | 2014-09-15 | 2017-11-24 | シナプティヴ メディカル （バルバドス） インコーポレイテッドＳｙｎａｐｔｉｖｅ Ｍｅｄｉｃａｌ （Ｂａｒｂａｄｏｓ） Ｉｎｃ． | System and method using composite optical probe |
| US9901406B2 (en) | 2014-10-02 | 2018-02-27 | Inneroptic Technology, Inc. | Affected region display associated with a medical device |
| JP6325423B2 (en) * | 2014-10-10 | 2018-05-16 | アズビル株式会社 | Liquid fluorescence detection apparatus and liquid fluorescence detection method |
| US10188467B2 (en) | 2014-12-12 | 2019-01-29 | Inneroptic Technology, Inc. | Surgical guidance intersection display |
| US10907122B2 (en) * | 2015-04-29 | 2021-02-02 | University Of Virginia Patent Foundation | Optical density system and related method thereof |
| CN104833670B (en) * | 2015-05-13 | 2017-08-01 | 中国人民解放军第二军医大学 | A kind of method of real-time of butyrate clevidipine bulk drug building-up process |
| US9949700B2 (en) | 2015-07-22 | 2018-04-24 | Inneroptic Technology, Inc. | Medical device approaches |
| CN113648067A (en) | 2015-11-13 | 2021-11-16 | 史赛克欧洲运营有限公司 | System and method for illumination and imaging of an object |
| WO2017127929A1 (en) | 2016-01-26 | 2017-08-03 | Novadaq Technologies Inc. | Configurable platform |
| US9675319B1 (en) | 2016-02-17 | 2017-06-13 | Inneroptic Technology, Inc. | Loupe display |
| US10293122B2 (en) | 2016-03-17 | 2019-05-21 | Novadaq Technologies ULC | Endoluminal introducer with contamination avoidance |
| WO2017173315A1 (en) | 2016-04-01 | 2017-10-05 | Black Light Surgical, Inc. | Systems, devices, and methods for time-resolved fluorescent spectroscopy |
| CN105954252B (en) * | 2016-04-21 | 2018-10-02 | 北京航空航天大学 | The qualitative checking method of illegal additive tonyred in a kind of feedstuff |
| USD916294S1 (en) | 2016-04-28 | 2021-04-13 | Stryker European Operations Limited | Illumination and imaging device |
| CA3027592A1 (en) | 2016-06-14 | 2017-12-21 | John Josef Paul FENGLER | Methods and systems for adaptive imaging for low light signal enhancement in medical visualization |
| US10278778B2 (en) | 2016-10-27 | 2019-05-07 | Inneroptic Technology, Inc. | Medical device navigation using a virtual 3D space |
| CA3049922A1 (en) | 2017-02-10 | 2018-08-16 | Novadaq Technologies ULC | Open-field handheld fluorescence imaging systems and methods |
| US11259879B2 (en) | 2017-08-01 | 2022-03-01 | Inneroptic Technology, Inc. | Selective transparency to assist medical device navigation |
| US11484365B2 (en) | 2018-01-23 | 2022-11-01 | Inneroptic Technology, Inc. | Medical image guidance |
| KR102234113B1 (en) * | 2018-02-08 | 2021-03-31 | 주식회사 스킨어세이 | Method and apparatus of Raman spectroscopy using broad band light excitation |
| US10952616B2 (en) | 2018-03-30 | 2021-03-23 | Canon U.S.A., Inc. | Fluorescence imaging apparatus |
| US10743749B2 (en) | 2018-09-14 | 2020-08-18 | Canon U.S.A., Inc. | System and method for detecting optical probe connection |
| EP3867631A4 (en) * | 2018-10-16 | 2022-07-20 | Polyvalor, Limited Partnership | Methods for performing a raman spectroscopy measurement on a sample and raman spectroscopy systems |
| US11446055B1 (en) | 2018-10-18 | 2022-09-20 | Lumoptik, Inc. | Light assisted needle placement system and method |
| EP3822717B1 (en) * | 2019-11-15 | 2022-09-07 | Sartorius Stedim Data Analytics AB | Method and device assembly for predicting a parameter in a bioprocess based on raman spectroscopy and method and device assembly for controlling a bioprocess |
| CN114651218B (en) * | 2019-11-15 | 2023-09-15 | 赛多利斯司特蒂姆数据分析公司 | Method and device assembly for predicting parameters in a biological process based on raman spectroscopy, and method and device assembly for controlling a biological process |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4479499A (en) * | 1982-01-29 | 1984-10-30 | Alfano Robert R | Method and apparatus for detecting the presence of caries in teeth using visible light |
| JPS5940830A (en) * | 1982-08-31 | 1984-03-06 | 浜松ホトニクス株式会社 | Apparatus for diagnosis of cancer using laser beam pulse |
| JPS60209146A (en) * | 1984-03-31 | 1985-10-21 | Olympus Optical Co Ltd | Fluorescence spectrochemical analysis device |
| SE455646B (en) * | 1984-10-22 | 1988-07-25 | Radians Innova Ab | FLUORESCENT DEVICE |
| US5192278A (en) * | 1985-03-22 | 1993-03-09 | Massachusetts Institute Of Technology | Multi-fiber plug for a laser catheter |
| US5104392A (en) * | 1985-03-22 | 1992-04-14 | Massachusetts Institute Of Technology | Laser spectro-optic imaging for diagnosis and treatment of diseased tissue |
| US5199431A (en) * | 1985-03-22 | 1993-04-06 | Massachusetts Institute Of Technology | Optical needle for spectroscopic diagnosis |
| US5318024A (en) * | 1985-03-22 | 1994-06-07 | Massachusetts Institute Of Technology | Laser endoscope for spectroscopic imaging |
| US5106387A (en) * | 1985-03-22 | 1992-04-21 | Massachusetts Institute Of Technology | Method for spectroscopic diagnosis of tissue |
| DE3650688T2 (en) * | 1985-03-22 | 1999-03-25 | Massachusetts Inst Technology | Fiber optic probe system for the spectral diagnosis of tissue |
| US4648892A (en) * | 1985-03-22 | 1987-03-10 | Massachusetts Institute Of Technology | Method for making optical shield for a laser catheter |
| US4967745A (en) * | 1987-04-10 | 1990-11-06 | Massachusetts Institute Of Technology | Multi-fiber plug for a laser catheter |
| US5034010A (en) * | 1985-03-22 | 1991-07-23 | Massachusetts Institute Of Technology | Optical shield for a laser catheter |
| US5125404A (en) * | 1985-03-22 | 1992-06-30 | Massachusetts Institute Of Technology | Apparatus and method for obtaining spectrally resolved spatial images of tissue |
| US4913142A (en) * | 1985-03-22 | 1990-04-03 | Massachusetts Institute Of Technology | Catheter for laser angiosurgery |
| AT387860B (en) * | 1985-09-16 | 1989-03-28 | Optical Sensing Technology | METHOD AND DEVICE FOR TUMOR DIAGNOSIS BY MEANS OF SERA |
| US5042494A (en) * | 1985-11-13 | 1991-08-27 | Alfano Robert R | Method and apparatus for detecting cancerous tissue using luminescence excitation spectra |
| US4930516B1 (en) * | 1985-11-13 | 1998-08-04 | Laser Diagnostic Instr Inc | Method for detecting cancerous tissue using visible native luminescence |
| JPH0765933B2 (en) * | 1986-08-01 | 1995-07-19 | 株式会社日立製作所 | Spectrofluorometer |
| GB8702441D0 (en) * | 1987-02-04 | 1987-03-11 | Univ Strathclyde | Cell screening |
| US4832483A (en) * | 1987-09-03 | 1989-05-23 | New England Medical Center Hospitals, Inc. | Method of using resonance raman spectroscopy for detection of malignancy disease |
| JPH01151436A (en) * | 1987-12-09 | 1989-06-14 | Hamamatsu Photonics Kk | Apparatus for diagnosis and treatment of cancer |
| JPH06105190B2 (en) * | 1988-03-31 | 1994-12-21 | 工業技術院長 | Signal analyzer |
| DE3815743A1 (en) * | 1988-05-07 | 1989-11-16 | Zeiss Carl Fa | DEVICE FOR MEASURING AND EVALUATING NATURAL FLUORESCENCE SPECTRES OF ORGANIC TISSUE SURFACES |
| US5036853A (en) * | 1988-08-26 | 1991-08-06 | Polartechnics Ltd. | Physiological probe |
| US5111821A (en) * | 1988-11-08 | 1992-05-12 | Health Research, Inc. | Fluorometric method for detecting abnormal tissue using dual long-wavelength excitation |
| US5386827A (en) * | 1993-03-30 | 1995-02-07 | Nim Incorporated | Quantitative and qualitative in vivo tissue examination using time resolved spectroscopy |
| WO1990006718A1 (en) * | 1988-12-21 | 1990-06-28 | Massachusetts Institute Of Technology | A method for laser induced fluorescence of tissue |
| US5026368A (en) * | 1988-12-28 | 1991-06-25 | Adair Edwin Lloyd | Method for cervical videoscopy |
| US5046501A (en) * | 1989-01-18 | 1991-09-10 | Wayne State University | Atherosclerotic identification |
| US5092331A (en) * | 1989-01-30 | 1992-03-03 | Olympus Optical Co., Ltd. | Fluorescence endoscopy and endoscopic device therefor |
| SE8900612D0 (en) * | 1989-02-22 | 1989-02-22 | Jonas Johansson | TISSUE CHARACTERIZATION USING A BLOOD-FREE FLUORESCENCE CRITERIA |
| EP0466828A1 (en) * | 1989-04-14 | 1992-01-22 | Massachusetts Institute Of Technology | Spectral diagnosis of diseased tissue |
| US5421337A (en) * | 1989-04-14 | 1995-06-06 | Massachusetts Institute Of Technology | Spectral diagnosis of diseased tissue |
| US5201318A (en) * | 1989-04-24 | 1993-04-13 | Rava Richard P | Contour mapping of spectral diagnostics |
| US5009655A (en) * | 1989-05-24 | 1991-04-23 | C. R. Bard, Inc. | Hot tip device with optical diagnostic capability |
| US4973848A (en) * | 1989-07-28 | 1990-11-27 | J. Mccaughan | Laser apparatus for concurrent analysis and treatment |
| US5369496A (en) * | 1989-11-13 | 1994-11-29 | Research Foundation Of City College Of New York | Noninvasive method and apparatus for characterizing biological materials |
| JP2852774B2 (en) * | 1989-11-22 | 1999-02-03 | 株式会社エス・エル・ティ・ジャパン | Diagnostic device for living tissue and treatment device provided with the diagnostic device |
| US5131398A (en) * | 1990-01-22 | 1992-07-21 | Mediscience Technology Corp. | Method and apparatus for distinguishing cancerous tissue from benign tumor tissue, benign tissue or normal tissue using native fluorescence |
| CA2008831C (en) * | 1990-01-29 | 1996-03-26 | Patrick T.T. Wong | Method of detecting the presence of anomalies in biological tissues and cells in natural and cultured form by infrared spectroscopy |
| US5168162A (en) * | 1991-02-04 | 1992-12-01 | Cornell Research Foundation, Inc. | Method of detecting the presence of anomalies in exfoliated cells using infrared spectroscopy |
| US5261410A (en) * | 1991-02-07 | 1993-11-16 | Alfano Robert R | Method for determining if a tissue is a malignant tumor tissue, a benign tumor tissue, or a normal or benign tissue using Raman spectroscopy |
| US5303026A (en) * | 1991-02-26 | 1994-04-12 | The Regents Of The University Of California Los Alamos National Laboratory | Apparatus and method for spectroscopic analysis of scattering media |
| ATE198375T1 (en) * | 1991-02-26 | 2001-01-15 | Massachusetts Inst Technology | MOLECULAR SPECTROSCOPY METHOD AND DEVICES FOR TISSUE DIAGNOSTICS |
| US5280788A (en) * | 1991-02-26 | 1994-01-25 | Massachusetts Institute Of Technology | Devices and methods for optical diagnosis of tissue |
| US5293872A (en) * | 1991-04-03 | 1994-03-15 | Alfano Robert R | Method for distinguishing between calcified atherosclerotic tissue and fibrous atherosclerotic tissue or normal cardiovascular tissue using Raman spectroscopy |
| US5318023A (en) * | 1991-04-03 | 1994-06-07 | Cedars-Sinai Medical Center | Apparatus and method of use for a photosensitizer enhanced fluorescence based biopsy needle |
| US5377676A (en) * | 1991-04-03 | 1995-01-03 | Cedars-Sinai Medical Center | Method for determining the biodistribution of substances using fluorescence spectroscopy |
| US5251613A (en) * | 1991-05-06 | 1993-10-12 | Adair Edwin Lloyd | Method of cervical videoscope with detachable camera |
| WO1993003672A1 (en) * | 1991-08-20 | 1993-03-04 | Redd Douglas C B | Optical histochemical analysis, in vivo detection and real-time guidance for ablation of abnormal tissues using a raman spectroscopic detection system |
| US5348018A (en) * | 1991-11-25 | 1994-09-20 | Alfano Robert R | Method for determining if tissue is malignant as opposed to non-malignant using time-resolved fluorescence spectroscopy |
| US5467767A (en) * | 1991-11-25 | 1995-11-21 | Alfano; Robert R. | Method for determining if tissue is malignant as opposed to non-malignant using time-resolved fluorescence spectroscopy |
| US5337745A (en) * | 1992-03-10 | 1994-08-16 | Benaron David A | Device and method for in vivo qualitative or quantative measurement of blood chromophore concentration using blood pulse spectrophotometry |
| US5452723A (en) * | 1992-07-24 | 1995-09-26 | Massachusetts Institute Of Technology | Calibrated spectrographic imaging |
| US5348003A (en) * | 1992-09-03 | 1994-09-20 | Sirraya, Inc. | Method and apparatus for chemical analysis |
| EP0608987B1 (en) * | 1993-01-26 | 2001-10-10 | Becton, Dickinson and Company | Method for detecting rare events |
| US5408996A (en) * | 1993-03-25 | 1995-04-25 | Salb; Jesse | System and method for localization of malignant tissue |
| US5413108A (en) * | 1993-04-21 | 1995-05-09 | The Research Foundation Of City College Of New York | Method and apparatus for mapping a tissue sample for and distinguishing different regions thereof based on luminescence measurements of cancer-indicative native fluorophor |
| US5421339A (en) * | 1993-05-12 | 1995-06-06 | Board Of Regents, The University Of Texas System | Diagnosis of dysplasia using laser induced fluoroescence |
| US5596992A (en) * | 1993-06-30 | 1997-01-28 | Sandia Corporation | Multivariate classification of infrared spectra of cell and tissue samples |
| ZA948393B (en) * | 1993-11-01 | 1995-06-26 | Polartechnics Ltd | Method and apparatus for tissue type recognition |
| US5421346A (en) * | 1993-11-23 | 1995-06-06 | Baylor College Of Medicine | Recovery of human uterine cells and secretions |
| US5590660A (en) * | 1994-03-28 | 1997-01-07 | Xillix Technologies Corp. | Apparatus and method for imaging diseased tissue using integrated autofluorescence |
| US5450857A (en) * | 1994-05-19 | 1995-09-19 | Board Of Regents, The University Of Texas System | Method for the diagnosis of cervical changes |
| US5498875A (en) * | 1994-08-17 | 1996-03-12 | Beckman Instruments, Inc. | Signal processing for chemical analysis of samples |
-
1995
- 1995-03-14 US US08/403,446 patent/US5697373A/en not_active Expired - Lifetime
-
1996
- 1996-03-08 EP EP96908539A patent/EP0765134B1/en not_active Expired - Lifetime
- 1996-03-08 WO PCT/US1996/002644 patent/WO1996028084A1/en active IP Right Grant
- 1996-03-08 JP JP8527642A patent/JPH10505167A/en not_active Ceased
- 1996-03-08 CA CA2190374A patent/CA2190374C/en not_active Expired - Fee Related
- 1996-03-08 DE DE69637163T patent/DE69637163T2/en not_active Expired - Lifetime
-
1997
- 1997-12-11 US US08/988,840 patent/US6095982A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69637163D1 (en) | 2007-08-30 |
| DE69637163T2 (en) | 2008-04-17 |
| CA2190374C (en) | 2010-07-13 |
| JPH10505167A (en) | 1998-05-19 |
| US6095982A (en) | 2000-08-01 |
| EP0765134B1 (en) | 2007-07-18 |
| US5697373A (en) | 1997-12-16 |
| WO1996028084A1 (en) | 1996-09-19 |
| EP0765134A1 (en) | 1997-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2190374A1 (en) | Optical method and apparatus for the diagnosis of cervical precancers using raman and fluorescence spectroscopies | |
| WO1996028084B1 (en) | Optical method and apparatus for the diagnosis of cervical precancers using raman and fluorescence spectroscopies | |
| Ramanujam et al. | Development of a multivariate statistical algorithm to analyze human cervical tissue fluorescence spectra acquired in vivo | |
| US6258576B1 (en) | Diagnostic method and apparatus for cervical squamous intraepithelial lesions in vitro and in vivo using fluorescence spectroscopy | |
| KR100415850B1 (en) | Cancer Diagnosis Device Using Laser-Induced Differential Normalized Fluorescence Spectrum | |
| CN102697510B (en) | Using-system fluorescence determines a certain glycation end product or morbid state | |
| US4930516A (en) | Method for detecting cancerous tissue using visible native luminescence | |
| US7236815B2 (en) | Method for probabilistically classifying tissue in vitro and in vivo using fluorescence spectroscopy | |
| US6421553B1 (en) | Spectral data classification of samples | |
| US8238993B2 (en) | Determination of a measure of a glycation end-product or disease state using tissue fluorescence lifetime | |
| US5042494A (en) | Method and apparatus for detecting cancerous tissue using luminescence excitation spectra | |
| CN100998499B (en) | Determination of a measure of a glycation end-product or disease state using tissue fluorescence | |
| US20020137993A1 (en) | Spectrum processing and processor | |
| CN1302210A (en) | Acetic acid as a signal enhancing contrast agent in fluorescence spectroscopy | |
| Carvalho et al. | In vivo Raman spectroscopic characteristics of different sites of the oral mucosa in healthy volunteers | |
| US20090317856A1 (en) | Multimodal Spectroscopic Systems and Methods for Classifying Biological Tissue | |
| Utzinger et al. | Performance estimation of diagnostic tests for cervical precancer based on fluorescence spectroscopy: effects of tissue type, sample size, population, and signal-to-noise ratio | |
| Drakaki et al. | Laser-induced fluorescence and reflectance spectroscopy for the discrimination of basal cell carcinoma from the surrounding normal skin tissue | |
| JPH09173301A (en) | Method for evaluating chapping of skin or damage and deterioration of hair or nail and device therefor | |
| Saraswathy et al. | Optimum wavelength for the differentiation of brain tumor tissue using autofluorescence spectroscopy | |
| Chowdary et al. | Autofluorescence of breast tissues: evaluation of discriminating algorithms for diagnosis of normal, benign, and malignant conditions | |
| JP2000325294A (en) | Method and device for outputting fluorescent diagnostic information | |
| Patalay et al. | Non-invasive imaging of skin cancer with fluorescence lifetime imaging using two photon tomography | |
| RU96114745A (en) | METHOD OF DIAGNOSTICS OF ONCOLOGICAL DISEASES AND DEVICE FOR ITS IMPLEMENTATION | |
| Jo et al. | Laguerre nonparametric deconvolution technique of time-resolved fluorescence data: application to the prediction of concentrations in a mixture of biochemical components |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDC | Correction of dead application (reinstatement) | ||
| MKLA | Lapsed |